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Abstract
Currently, thirty-seven million people are infected with human immunodeficiency virus-1 (HIV-1)
worldwide. Thankfully, the development of combined antiretroviral therapy (cART) regimens has decreased
mortality and significantly improved the overall quality of life for these patients. However, approximately half
of all patients clinically manifest with HIV-associated neurocognitive disorder (HAND), a spectrum of
cognitive, motor, and behavioral abnormalities which histologically present as non-specific gliosis,
synaptodendritc damage and loss of white matter and myelin. Furthermore, the severity of white matter
damage correlates with the length of ART duration. However, almost no studies have been performed to
determine how the myelin sheath or the oligodendrocytes that synthesize the sheath are damaged. Thus, we
hypothesized that the administration of ART contributed in part to the myelin loss in the CNS of HIV-
positive patients. Previously, we have reported that the protease inhibitor class of ART drugs hampered the in
vitrodifferentiation of oligodendrocytes. Given that the new US guidelines for treating HIV patients
recommends anew class of drugs, the integrasestrand transferinhibitors(INSTIs)as front-line therapy, we
examined if two specific INSTIs, Elvitegravir (EVG) and raltegravir (RAL), altered the survival and/or
maturation of developing oligodendrocytes in vitroand in vivo. We found that treatment of oligodendrocyte
precursor cells (OPCs) with EVG, but not RAL, during differentiation reduced the number of cells positive
for immature oligodendrocyte marker galactosylceramide (GalC) and mature oligodendrocyte marker myelin
basic protein (MBP) in vitro, as well as the synthesis of myelin proteins. However, neither EVG or RAL
induced cell loss or apoptosis, as determined by cell counts and TUNEL assays, suggesting that EVG does not
affect OPC viability but instead, inhibits differentiation. EVG-induced oligodendrocyte differentiation deficits
could be reversed by pre-treating the cells with a drug that pharmacologically inhibits the phosphorylation of
eukaryotic initiation factor 2α(eIF2α) throughthe cellular integrated stress response (ISR). Finally, in
vivo,mice receiving EVG/COBI failed to remyelinate the corpus callosum during the three week recovery
period following demyelination, after cuprizone treatment. Although EVG/COBI treatment by itself did not
cause overt white matter loss in this brain region. Our study demonstrates that EVG, but not RAL, inhibits
oligodendrocyte precursor cell differentiation both in vitroand in vivo. Furthermore, EVG may be inhibiting
oligodendrocyte precursor cell differentiation though activation of the ISR. Also, we found thatthe effects of
EVG on oligodendrocyte differentiation could be attenuated in vitroby inhibiting the ISR. These studies
suggest that ART may contribute to cognitive impairment by inhibiting renewal and replacement of
oligodendrocytes in adults or development of oligodendrocytes in children. Further, our results suggest an
ISR inhibitor might attenuate the negative effect of EVG on the maturation of oligodendrocytes. Our findings
also suggest that development of less toxic ART compounds and adjunctive therapies are needed to minimize
the side effects of ART on the CNS.
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ABSTRACT: 
Currently, thirty-seven million people are infected with human 
immunodeficiency virus-1 (HIV-1) worldwide. Thankfully, the development of 
combined antiretroviral therapy (cART) regimens has decreased mortality and 
significantly improved the overall quality of life for these patients. However, 
approximately half of all patients clinically manifest with HIV-associated 
neurocognitive disorder (HAND), a spectrum of cognitive, motor, and 
behavioral abnormalities which histologically present as non-specific gliosis, 
synaptodendritc damage and loss of white matter and myelin. Furthermore, 
the severity of white matter damage correlates with the length of ART 
duration. However, almost no studies have been performed to determine how 
the myelin sheath or the oligodendrocytes that synthesize the sheath are 
damaged. Thus, we hypothesized that the administration of ART contributed 
in part to the myelin loss in the CNS of HIV-positive patients. Previously, we 
have reported that the protease inhibitor class of ART drugs hampered the in 
vitro differentiation of oligodendrocytes. Given that the new US guidelines for 
treating HIV patients recommends a new class of drugs, the integrase strand 
transfer inhibitors (INSTIs) as front-line therapy, we examined if two specific 
INSTIs, Elvitegravir (EVG) and raltegravir (RAL), altered the survival and/or 
maturation of developing oligodendrocytes in vitro and in vivo. We found that 
treatment of oligodendrocyte precursor cells (OPCs) with EVG, but not RAL, 
during differentiation reduced the number of cells positive for immature 
oligodendrocyte marker galactosylceramide (GalC) and mature 
oligodendrocyte marker myelin basic protein (MBP) in vitro, as well as the 
synthesis of myelin proteins. However, neither EVG or RAL induced cell loss 
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or apoptosis, as determined by cell counts and TUNEL assays, suggesting 
that EVG does not affect OPC viability but instead, inhibits differentiation. 
EVG-induced oligodendrocyte differentiation deficits could be reversed by pre-
treating the cells with a drug that pharmacologically inhibits the 
phosphorylation of eukaryotic initiation factor 2 α (eIF2α) through the cellular 
integrated stress response (ISR). Finally, in vivo, mice receiving EVG/COBI 
failed to remyelinate the corpus callosum during the three week recovery 
period following demyelination, after cuprizone treatment. Although 
EVG/COBI treatment by itself did not cause overt white matter loss in this 
brain region. Our study demonstrates that EVG, but not RAL, inhibits 
oligodendrocyte precursor cell differentiation both in vitro and in vivo. 
Furthermore, EVG may be inhibiting oligodendrocyte precursor cell 
differentiation though activation of the ISR. Also, we found that the effects of 
EVG on oligodendrocyte differentiation could be attenuated in vitro by 
inhibiting the ISR. These studies suggest that ART may contribute to cognitive 
impairment by inhibiting renewal and replacement of oligodendrocytes in 
adults or development of oligodendrocytes in children. Further, our results 
suggest an ISR inhibitor might attenuate the negative effect of EVG on the 
maturation of oligodendrocytes. Our findings also suggest that development of 
less toxic ART compounds and adjunctive therapies are needed to minimize 
the side effects of ART on the CNS. 
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CHAPTER 1: Introduction 
1.1 Overview: 
Since the isolation of Human Immunodeficiency virus (HIV) three decades 
ago, research has revealed many aspects of this virus including the 
interaction with host cells and other pathogenic mechanisms. HIV is a 
lentivirus within the family of retroviridae, it’s a single strand RNA virus 
which has two types, HIV-1 and HIV-2 [1]. Like other retroviruses HIV-1 
virions contain two copies of a single-stranded RNA genome, which is 
reversely transcribed to double-stranded DNA by the viral reverse 
transcriptase enzyme. This double-stranded DNA fragment is subsequently 
integrated into the host genome by the viral integrase enzyme [2]. Although 
HIV-induced abnormalities do not manifest in the CNS until the later stages of 
infection, there is evidence to support early entry of virus into the CNS in HIV-
1 positive patients [3]. However, the major impact of HIV on neuronal cells 
likely occurs indirectly through release of excitotoxic substances from HIV 
infected macrophages [4-7]. A major manifestation of HIV in the CNS is HIV 
associated neurocognitive disorder (HAND) [8]. The development of 
combined antiretroviral therapy (cART) transformed the HIV infection from a 
lethal disease into a chronic illness managed by medication [9]. cART is a 
combination of antiretroviral compounds that target different points in the viral 
life cycle and fall into several categories: 
1. Nucleoside reverse transcriptase inhibitors (NRTIs)  
2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)  
3. Protease inhibitors (PIs)  
4. Integrase inhibitors (INSTIs)  
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5. Fusion inhibitors (FIs)  
6. Chemokine receptor antagonists (CCR5 antagonists) 
It has been found that using multiple classes of ART is more effective at viral 
suppression compared with treatment using a single class [10]. Despite viral 
suppression with cART, about 50% of HIV-positive patients still suffer from 
HAND. Previously, our lab showed that using ritonavir (RIT) (a protease 
inhibitor) had a negative effect on the differentiation of oligodendrocytes 
suggesting that RIT contributed to the loss of white matter in HAND [11]. One 
of the prominent cellular stress responses associated with ART treatment is 
ER stress, generated from the accumulation of unfolded proteins inside the 
lumen of ER, which is a candidate for the major underlying mechanism for 
much of the damage observed in the CNS of patients with HAND receiving 
ART in their treatment for HIV [12]. Another potential factor that contributes to 
the neurological damage in HAND is through disturbance of lipid balance in 
the oligodendrocytes in patients using RIT as part of their cART regimen [13]. 
We hypothesized that different classes of cART compounds activate different 
cellular stress pathways in oligodendrocytes. Attenuating these stresses could 
have a therapeutic impact and could ameliorate negative effects of cART 
drugs on oligodendrocytes. 
 
1.2 HIV-Associated Neurocognitive Disorder (HAND) 
According to the latest statistics from the world health organization (WHO), 
thirty-seven million people are infected with human immunodeficiency virus-1 
(HIV-1) worldwide[14]. Approximately half of all HIV-positive patients clinically 
present with a neurological manifestation called HIV-associated 
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neurocognitive disorder (HAND), a spectrum of cognitive, motor, and 
behavioral abnormalities associated with white matter loss [8]. HIV enters the 
brain within the first two weeks of infection [15]. Several mechanisms have 
been proposed in the literature to explain how HIV infects the CNS. One 
theory holds that the virus can infect the endothelial layer of the blood brain 
barrier (BBB) and damaging the endothelial layer by the virus results in easier 
access of the virus to the CNS [16]. Another theory suggests that the HIV 
disrupts the lipid rafts in the cell membrane of the endothelial layer of BBB 
which is an important portal into the CNS [17]. Lastly, the most widely 
accepted theory is the “Trojan horse” theory, through which HIV-1 infected 
monocytes pass through the BBB leading to subsequent viral release and 
propagation in the CNS with the pool of infected macrophages spreading HIV 
infection inside the brain [18]. In the CNS, the virus can infect macrophages, 
microglia, and a small proportion of astrocytes. However, HIV-1 has not been 
known to elicit any direct effects on neurons or oligodendrocytes [19-21]. Two 
proposed mechanisms explain the effects of the HIV on the neuronal cells, the 
first proposed mechanism is through direct injury from HIV proteins (e.g. 
gp120, Tat, and Vpr) released from infected macrophages and microglia 
which interact with receptors on neurons. The second proposed mechanism is 
the “bystander effect” hypothesis, which suggests that the damage occurs due 
to the release of cytotoxic molecules including reactive oxygen species, nitric 
oxide, glutamate, and pro-inflammatory cytokines and chemokines from the 
infected immune cells in the CNS, leading to neuronal damage and 
dysfunction [7]. Both direct viral protein effects and indirect bystander effects 
of HIV have been documented in the literature and result in HIV-mediated 
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neuronal toxicity in HAND patients [22]. HAND severity is clinically divided into 
three categories based on two specific factors: patient neurocognitive status 
and patient functional status. Based off of these two criteria, patients can be 
diagnosed as having Asymptomatic Neurocognitive Impairment (ANI), Mild 
Neurocognitive Disorder (MND), or HIV Associated Dementia (HAD). HAD is 
considered the most severe form of HAND (Table1) [8]. 
 Neurocognitive Status  Functional Status 
Asymptomatic 
Neurocognitive 
Impairment (ANI) 
1 SD below mean, 2 
cognitive domains 
No impairment in 
activities of daily living 
Mild Neurocognitive 
Disorder (MND) 
1 SD below mean, 2 
cognitive domains 
Impairment in activities 
of daily living 
HIV Associated 
Dementia (HAD) 
2 SD below mean, 2 
cognitive domains 
Marked impairment in 
activities of daily living 
Table 1: Categories of HIV associated neurocognitive disorder HAND. 
Neurocognitive status included test of at least five domains such as language, 
attention-formation processing and simple motor skills. The functional status 
is usually evaluated by self-report.  
  
HAD incidence significantly decreased during the post-cART era [8, 23]. 
Currently, CD4+ T-lymphocyte cell counts are no longer a marker for HAND 
severity. Instead, cerebrospinal fluid (CSF) analysis and neuroimaging 
techniques can be utilized to detect pathological changes in the CNS. This 
has proven especially useful for patients with accelerated progression of 
dementia. Before the cART era, approximately 25% of HAND positive patients 
had the severe form of HAND (HAD) with neuronal death observed in the 
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frontal lobes, hippocampus, and basal ganglia [24]. Since cART introduction 
in the mid 1990s, an extensive clinical investigation has revealed a dramatic 
reduction in the prevalence of HAD (specifically, to only 2% of HIV-1 positive 
patients). However, the milder forms of HAND became more predominant, 
with a shift from pre-cART subcortical pathology to cortical manifestations with 
cART. It is also interesting to note that the percent of HIV-1 patients with 
HAND remains unchanged from the pre-ART to the post-ART eras [25-29].  
CNS damage in the post-cART era has been attributed to multiple factors 
such as irreversible brain impairment prior to cART initiation, poor CNS 
penetrance of several ART drugs, and inadequate viral elimination from CNS. 
More importantly, ART drugs themselves have been shown to have 
deleterious effects on the CNS [7, 11, 12, 30, 31].  
 
1.3 Antiretroviral Therapy:  
Prior to 1990s, HIV-1 antiretroviral drugs were administered as a 
monotherapy, but due to the error-prone reverse transcription process during 
viral replication, HIV is highly susceptible to mutations. However, in the late 
1990s, the standard of care changed such that several ART drugs could be 
administered with a lower pill burden to combat HIV-1, which became known 
as combined antiretroviral therapy (cART) to overcome the high mutation rate 
of HIV [32]. This multiple-hit approach targets the virus at several different 
biological processes to control viral replication, and to transform HIV-1 
infection from a lethal illness into a chronic, yet manageable disorder [33-35]. 
It is important that after cART initiation, treatment should not be interrupted. 
ART cessation has been associated with opportunistic infections and further 
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immune system compromise [36]. ART has no therapeutic effect on 
previously infected cells, but it prevents further HIV-1 infection of new target 
cells with high efficacy [37]. ART drugs have been designed to 
simultaneously target the virus at one of the five stages of the HIV-1 life cycle, 
viral entry, reverse transcription, viral DNA integration into the host genome, 
transcription, virus assembly/production, and proteases [32, 38]. The multiple 
classes of ART suppress the virus in different ways (Figure 1); the entry 
inhibitor class interferes with viral entrance into the host cell. It works by 
inhibiting virus attachment to the CD4 receptor, and co-receptor CC-
chemokine receptor 5 (CCR5) or CXC-chemokine receptor 4 (CXCR4) which 
is necessary for fusion of the virus to the target cell membrane [39]. The 
Nucleoside reverse transcriptase inhibitors (NRTIs) mimic endogenous 
deoxyribonucleotides and are characterized by having high affinity for the 
virus reverse transcriptase enzyme, which facilitates incorporation into the 
viral DNA strand during synthesis [40]. Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), unlike NRTIs, disrupt the enzymatic activity of the viral 
reverse transcriptase [41]. Integrase strand transfer inhibitors (INSTIs) are 
one of the more recently-developed classes of antiretrovirals. These drugs 
inhibit the HIV-1 integrase enzyme, which is important for viral DNA 
integration into the cell genome. Specific drugs in this class include 
Elvitegravir (EVG) and Raltegravir (RAL). Integrase inhibitors bind to cofactors 
of the viral integrase enzyme that are important for interaction with the host 
DNA resulting in blocking the insertion of the virus into the host genome [42]. 
The protease inhibitor (PI) class has a high affinity for the HIV protease active 
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site. Inhibiting this enzyme prevents HIV maturation and subsequent viral 
budding (Figure 1) [43]. 
 
 
Figure 1: Classes of ART; Treatment of HIV infected patients is usually a 
combination of these classes that aim at suppressing the life cycle of the virus 
at different points.  
 
These drugs are usually prescribed with pharmacokinetic boosters, such as 
the P450 inhibitors Cobicistat (COBI) or RIT [44]. Both COBI and RIT are 
potent inhibitors of the cytochrome P450 isoenzyme and achieve the desired 
goal of boosting plasma drug concentrations, but COBI is more selective than 
RIT to P450 [45, 46]. A proposed cause for the persistence of the viral effects 
in the CNS is limited penetration of ART into CNS because of the presence of 
BBB. For this reason, a proposed method to eliminate viral reservoirs is to 
apply therapies with ART that would reach therapeutic concentrations in the 
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CNS tissue of infected patients [47]. To address the issue of ART penetration 
into the CNS, a CNS penetration effectiveness (CPE) score was developed 
based on 1) Chemical properties of the drug, 2) Concentration of the drug in 
CSF, and 3) Effectiveness of the drug to reduce the viral load in CSF [48]. 
One of the examples for that is EVG, a small lipophilic molecule that has been 
characterized to have a high CPE score [9, 49]. Still CPE scores do not 
completely correlate with CNS neurological functions, since several ART 
drugs with high CPE were associated with worse neurocognitive performance 
[50]. Our knowledge of the effects of CPE scores on neurological outcomes in 
human patients is limited due to technical and ethical limitations. Moreover, 
other factors are not included when evaluating the CPE such as drug and 
alcohol abuse, co-infections, and, most importantly, the integrity of BBB [51, 
52]. Toxic effects of ART in the CNS have not been studied thoroughly, 
however with the periphery as an indicator it is likely that ARV drugs have the 
capacity to contribute to neuronal damage and manifestations of HAND.  
 
1.4 The Integrated Stress Response (ISR) 
One of the protective cellular mechanisms in response to different stressors is 
the activation of a common adaptive pathway termed the integrated stress 
response (ISR). Extracellular and intracellular stressors such as hypoxia, 
amino acid deprivation, glucose deprivation, viral infection, or the 
accumulation of unfolded proteins in the ER can activate this pathway [53]. 
The pathway is initiated by one of four protein sensors in unstressed cells. 
These four proteins are PKR-like ER kinase (PERK), double-stranded RNA-
dependent protein kinase (PKR), heme-regulated eIF2α kinase (HRI), and 
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general control nonderepressible 2 (GCN2) (Figure 2) [53, 54]. The common 
point where these kinases converge to activate ISR is the phosphorylation of 
eukaryotic translation initiation factor 2 subunit alpha (eIF2α) on serine 51 
[55]. Each of these kinases are activated by different stressors. PERK can be 
activated by accumulation of unfolded proteins in the lumen of ER, 
perturbations in calcium homeostasis, or changes in cellular energy or redox 
status [56]. There are two models of activation of PERK through ER stress. 
The classical model is through the accumulation of incompletely folded or 
unfolded proteins in the lumen of ER leading to dissociation of GRP78 from 
PERK leading to activation and autophosphorylation [57, 58]. However, 
another model suggests that PERK is activated directly by binding of unfolded 
proteins to its luminal domain [56]. GCN2 becomes activated in response to 
amino acid deprivation [59]. PKR is activated mainly by double strand RNA 
viruses [60, 61]. Unlike other kinases, stressors like ER stress, oxidative 
stress, growth factor deprivation and bacterial infection can also activate PKR 
kinase in a dsRNA-independent manner [62]. HRI is activated upon heme 
deprivation leading to dimerization and autophosphorylation of its kinase 
domain [63]. In the ISR, restoring normal cellular function is performed by 
dephosphorylating eIF2α, which is accomplished by protein phosphatase 1 
(PP1), PPP1R15A (known as GADD34), or PPP1R15B (known as CReP). 
CReP operates under resting-state conditions to maintain a low level of eIF2α 
phosphorylation, unlike GADD34. GADD34 expression is induced at later 
stages of the ISR, acting as part of an important negative feedback loop to 
restore normal protein synthesis once the stress has been resolved (Figure 2) 
[64, 65].  
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Figure 2: Integrated Stress Response (ISR): ISR is a common pathway 
activated for adaptation to various intrinsic and extrinsic stressors. These 
stressors activate one of four kinases which are PKR-like ER kinase (PERK), 
double-stranded RNA-dependent protein kinase (PKR), heme-regulated 
eIF2α kinase (HRI), and general control nonderepressible 2 (GCN2). The 
common point where these kinases converge to activate ISR is the 
phosphorylation of eukaryotic translation initiation factor 2 (eIF2α). Cellular 
normal function will be restored upon dephosphorylating eIF2α and in case of 
persistence of the stress, ATF4 will mediate cell death through activation of 
CHOP. 
 
1.4a ISR Activation by ART Drugs 
ART has improved the quality of life of HIV-positive patients and transformed 
HIV from a mortal disease into a chronic disease. However, a large number of 
studies show that ART contributes to other conditions such as HAND, 
dyslipidemia and other disorders [11, 66, 67]. A few previously published 
studies show that different classes of ART are responsible for activation of 
different stress pathways in neural cells. RIT from the PI class inhibits the 
differentiation of oligodendrocytes through an as yet unidentified pathway[11] 
and lopinavir and EVG are toxic to neurons [12]. Another study performed on 
primary neurons showed that EVG treatment decreased the maturation and 
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elongation of neuronal processes and activated the ISR, as assessed by 
measuring the levels of phosphorylated eIF2α. Most notably, the effects from 
EVG treatment were significantly reduced after pharmacologically blocking 
eIF2α phosphorylation with a drug called TRANS-ISRIB.[12] However, the 
literature on the effects of HIV ART on the different stress pathways in the 
CNS is incomplete. 
 
1.5 White matter pathologies in HAND 
During HIV-1 infection/HAND, white matter changes compromised structural 
integrity and volume of corpus callosum, internal capsule, superior 
longitudinal fasciculus, superior corona radiata, as well as reduction in overall 
blood flow to white matter. Cognitive impairment was positively correlated with 
white matter injury, but not to the viral load [11, 68-73]. Furthermore, a recent 
transcriptome analysis identified genes which remain dysregulated in HAND-
afflicted individuals on ART including important myelin genes such as myelin-
associated oligodendrocyte basic protein, myelin transcription factor 1, and 
myelin basic protein [74]. One of the earlier treatment regimens for HIV (which 
is still part of the World Health Organization treatment guidelines) includes 
RIT and lopinavir [14]. Treatment with these protease inhibitors caused a 
reduction in the maturation and differentiation of OPCs in vitro and RIT 
treatment reduced myelin protein expression in vivo [11, 75]. The new 
guidelines for patients with HIV infection include a more recently-introduced 
class of drugs called integrase strand transfer inhibitors (INSTIs) which inhibit 
the integrase enzyme encoded by the virus to integrate its genome into the 
host cell DNA, which is an essential process for HIV replication [9, 44]. Here, 
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we test two different INSTIs: EVG and RAL, and their effects on OPC survival 
and differentiation in vitro using primary rat cortical cell culture model, and the 
effects of EVG combined with P450 inhibitor, cobicistat, to examine the effect 
of the drug on the myelination of oligodendrocytes in a cuprizone mouse 
model [76, 77].  
 
1.6 Sterol regulatory element-binding protein (SREBP) pathway 
The myelin in mammals is synthesized by two types of cells, oligodendrocytes 
in the CNS and Schwann cells in the peripheral nervous system (PNS) and is 
a lipid rich and multilamellar structure. Beside providing nutrition and support, 
oligodendrocytes and Schwann cells play a major role in insulating the nerve 
axon to improve electrical conductivity. Myelin plays a major role in higher 
brain function and a reduction in the myelin production is associated with 
diseases such as multiple sclerosis (MS) [78]. The plasma membrane of 
oligodendrocytes differs from other cells due to the presence of a high lipid 
content in its membrane [79]. During myelination, oligodendrocytes generate 
tremendous amount of lipids in a short period of time [80]. Unlike other cells, 
the protein to lipid ratio is 1 to 186 due to the compact function of the most 
abundant proteins in myelin MBP and PLP [81]. Quantitively, the most 
abundant lipids in myelin are cholesterol and fatty acids. The cholesterol 
provides the stability to myelin through regulating permeability and fluidity of 
the membrane, the rate of cholesterol synthesis appears to couple with the 
speed of myelin membrane biogenesis [82]. Knocking out fatty acid synthesis 
in mice is embryonically lethal, and resulted in reduced thickness of the 
myelin wrapping of nerve axons [83, 84]. The intracellular levels of both 
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cholesterol and fatty acids are precisely controlled through a feedback system 
facilitated by a family of transcription factors called sterol regulatory element-
binding proteins (SREBPs) which are members of the basic helix-loop-helix-
leucine zipper (bHLH-Zip) transcription factor family. SREBPs are found as 
inactive precursors bound to the ER membrane. A reduction in cholesterol 
and fatty acids results in activation of SREBPs through their translocation 
from the ER membrane to the Golgi apparatus where they are cleaved by site 
1 protease (S1P) and site 2 protease (S2P). S1P cleaves SREBPs in the 
luminal loop between the two membrane-spanning sequences, whereas S2P 
cleaves the NH2-terminal bHLH-Zip domain of SREBPs, releasing the mature 
forms. The mature NH2-terminal domain then translocates to the nucleus to 
activate genes controlling lipid synthesis. In contrast, excess of lipids will 
result in SREBP inactivation to inhibit the accumulation of the lipids in the cell 
[85]. Cholesterol synthesis is controlled by two intracellular sensors; Insig and 
Scap. In case of cholesterol depletion, Insig-1 dissociates from Scap and is 
degraded by proteasomes, whereas the Scap/SREBP complex exits the ER 
and is transported to the Golgi apparatus where it is cleaved by both S1P and 
S2P and the active domain transfers into the nucleus to restore the 
cholesterol levels in the cell [86]. After sufficient production of cholesterol Insig 
binds to Scap forming Insig/Scap complex in the ER [87]. In sterol and fatty 
acid depleted cells, Insig is ubiquitinated by gp78. Ubiquitin regulatory X 
domain-containing protein 8 (Ubxd8) recruits the ATPase p97 to Insig leading 
to degradation of Insig by proteasomes, whereas this action is inhibited by the 
presence of unsaturated fatty acids and sterols [88]. Excess lipids in the body 
is a risk factor for developing disorders such as atherosclerosis which is a life 
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threatening disease, which results from lipid accumulation in the 
subendothelial matrix [89, 90]. An increase in the synthesis of fatty acids in 
the tissue is also associated with improper brain development besides other 
tissue dysfunctions [91]. 
 
1.7 Oligodendrocytes in HAND: 
Oligodendrocytes are one of the four glial cells in the CNS, accounting for 5-
8% of all glial cells [92]. Oligodendrocytes develop prenatally and early in 
postnatal life, and during development. Neural progenitor cells (NPCs) give 
rise to neurons and glial cells. However, oligodendrocytes are derived from 
oligodendrocyte precursor cells (OPCs). The three main stages of 
oligodendrocyte differentiation are: oligodendrocyte precursor cells (OPCs), 
immature oligodendrocytes, and mature oligodendrocytes [93]. 
Oligodendrocytes are generated from OPCs and mature in a stage-specific 
process, allowing for assessment using stage specific antigens. As they 
differentiate, they start expressing markers such as A2B5, NG2 and PDGF-A. 
As they transition into the immature stage, they express GalC and start to 
extend their processes to adopt the morphology of the mature phase which is 
characterized by the presence of PLP and MBP proteins (Figure 3) [94]. 
Ultimately, these proteins will form the myelin sheath as part of the 
oligodendrocyte plasma membrane. OPC founder cells arise from the 
ventricular region early during development as a result of local signaling by 
factors including sonic hedgehog. The immature oligodendrocyte is suggested 
to be highly migratory, and the final matching between oligodendrocytes and 
nerve axons happens due to combination of local regulation of cell 
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proliferation and differentiation [95]. The wrapping of multiple nerve axons by 
a solitary oligodendrocyte is a heavily synchronized event. Oligodendrocytes 
do not wrap different nerve axons at different time points. Rather, it is done 
within a short period of time, typically within 12 to 18 hours [96]. In the CNS, a 
single oligodendrocyte can produce as many as forty segments on multiple 
axons. The main elements of myelin in the oligodendrocytes are lipids, which 
account for at least 70% of dry weight, which is considered to be twice as 
concentrated as other plasma membranes.  
Myelin’s main function is to insulate the nerve axons to increase the 
electrical resistance in the cell membrane and decrease membrane 
capacitance to ensure fast conduction of electrical impulses [97, 98]. The 
myelin sheath also supplies nutrition and support for nerve axons[95]. Re-
myelination or myelin repair of the nerve axons enables restoration of 
saltatory conduction, and a return of normal function lost during demyelination 
[92, 99]. Remyelination of the nerve axons after injury is not performed by 
mature oligodendrocytes, but rather by the OPCs distributed throughout the 
CNS.  
Oligodendrocytes are thought to be not directly infected by HIV. Similar 
to neurons, oligodendrocytes lack the CD4 receptor required for HIV entry, 
suggesting that in these two populations indirect injury results from infected 
cells in the CNS [100]. The synaptodendritc injury in HAND is largely 
mediated by infected and activated microglia and astrocytes. In culture, HIV-1 
Tat caused death of immature oligodendrocytes, while more mature OLs 
remained alive with dysregulated myelin protein and morphology [101]. In 
humans, the transcriptome analysis showed an alteration in oligodendrocyte 
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specific genes following HIV-infection in HAND patients, this alteration 
remained even after suppression of the virus with ART [74]. Our studies 
demonstrate that selected ART drugs inhibit oligodendrocyte precursor cell 
differentiation, suggesting that it might contribute to the development of 
HAND. In vitro we were able to rescue the differentiation of oligodendrocytes 
from the effects of one ART drug. Our findings also suggest that development 
of less toxic ART compounds and adjunctive therapies are needed to 
minimize the side effects of ART in the CNS. 
 
 
Figure 3: Progression of oligodendrocyte lineage from OPCs to mature cells;  
specific markers found at different stages of maturation of oligodendrocytes 
during their development. Monitoring these markers, using specific antibodies, 
allows for studies to be performed evaluating maturation from oligodendrocyte 
precursor cells to immature and mature oligodendrocytes.  
 
  
31 
  
CHAPTER 2: The role of specific Integrase Strand 
Transfer Inhibitors (INSTIs) in modulating oligodendrocyte maturation 
and myelination in HAND 
2.1 Abstract 
Despite effective viral suppression through combined antiretroviral (ARV) 
therapies (cART), approximately half of HIV-positive individuals present with 
HIV-associated neurocognitive disorder (HAND), a spectrum of cognitive, 
motor, and behavioral disturbances. Clinical manifestations of HAND include 
non-specific gliosis, synaptodendritic damage, and myelin loss. Studies of 
cART-treated patient brains have shown persistent myelin abnormalities 
including the thinning of the corpus callosum, and decreased myelin protein 
mRNAs. The myelin membrane, produced by oligodendrocytes, is critical for 
rapid action potentials and axonal maintenance; thus, myelin loss can 
contribute to neurocognitive dysfunction. We have previously shown that ART 
compounds from the protease inhibitor (PI) class, ritonavir, attenuated 
maturation of oligodendrocytes, in vitro and in vivo. Current guidelines for 
cART regimens recommend a new class of ART compounds, the integrase 
strand transfer inhibitors (INSTIs). We hypothesized that INSTIs also alter 
maturation and/or survival of oligodendrocytes, contributing to the myelin loss 
seen in HAND patients. To address this question, we induced differentiation of 
primary rat oligodendrocyte progenitor cells in the presence or absence of 
therapeutically relevant concentrations of INSTIs elvitegravir and raltegravir.  
We found that INSTI raltegravir had no effect, while elvitegravir treatment 
resulted in a dose-dependent reduction in mature oligodendrocytes after three 
days. In vivo daily administration of elvitegravir to adult mice in the three 
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weeks following cuprizone-induced demyelination, resulted in reduced 
remyelination compared with cuprizone treated animals permitted to recover 
or treated with the vehicle. Elvitegravir treatment resulted in activation of the 
integrated stress response (ISR) in both our in vitro model of oligodendrocyte 
development and our in vivo model of remyelination. Blocking ISR with the 
inhibitor, Trans-ISRIB, rescued oligodendrocyte maturation in the presence of 
elvitegravir in vitro. These studies suggest that elvitegravir inhibits the 
maturation of oligodendrocyte precursor cells and subsequent myelination by 
oligodendrocytes. 
 
Significance Statement 
HIV-associated neurocognitive disorder (HAND) represents a spectrum of 
cognitive, motor, and behavioral disturbances that occur in approximately 
50% of HIV-positive individuals, regardless of the consistent administration of 
combined antiretroviral (ARV) therapies (cART). The etiology and 
pathogenesis of HAND are currently unknown; however, soluble factors from 
HIV-infected macrophages/microglia and potentially cART themselves may 
play a role. Herein, we show that maturing oligodendrocytes treated with a 
front line ART compound, elvitegravir, are inhibited from differentiating into 
immature and mature oligodendrocytes. In vivo administration of elvitegravir 
to mice recovering from cuprizone-induced demyelination leads to attenuation 
of remyelination. We also show that elvitegravir treatment induces the 
integrated stress response (ISR) in oligodendrocytes in vitro and in vivo. 
Further, pretreatment with an ISR inhibitor, trans-ISRIB, prior to elvitegravir 
treatment, rescued maturation attenuation induced by elvitegravir in vitro. 
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2.2 Introduction 
Despite effective viral suppression by combined antiretroviral (ARV) therapy 
(cART), approximately 50% of HIV-positive patients present with a broad 
spectrum of cognitive, motor, and behavioral disturbances collectively termed 
HIV-associated neurocognitive disorder (HAND) [8, 102-104]. Due to the high 
mutation rate during HIV replication, cART is designed to target multiple 
processes in the replication cycle of the virus to reduce drug resistance [105]. 
The newest class of ART compounds, the integrase strand transfer inhibitors 
(INSTIs), inhibits the function of the virally-encoded HIV integrase enzyme 
which mediates integration of the reverse transcribed viral DNA into the host 
cell genome [44, 105]. Current front-line cART regimes include two 
compounds from the nucleoside reverse transcriptase (NRTI) class and one 
from the INSTI class, making these compounds clinically relevant to study 
[14]. In the post cART era, HAND neuropathogenesis includes persistent 
microgliosis, astrogliosis, dendritic damage, neuronal, loss, synaptic loss and 
white matter abnormalities [8, 106, 107]. White matter changes include 
dramatic thinning of the corpus callosum and loss of structural integrity and 
volume of frontal white matter [68, 70, 72, 108]. Notably, the severity of 
cognitive impairment correlates with the amount of white matter damage 
[109]. Furthermore, a recent transcriptome analysis identified myelin-
associated oligodendrocyte basic protein, myelin transcription factor 1, and 
myelin basic protein (MBP) as being reduced in patients with HAND 
regardless of cART [110]. In the CNS, oligodendrocytes are non-neuronal 
cells that produce white matter or myelin; this mostly lipid-based membrane is 
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critical for the rapid transmission of action potentials, metabolic support, and 
prevention of axonal degeneration [111-113].  
Even with growing evidence of persistent myelin abnormalities in HAND 
individuals, the mechanism underlying these observed changes remains 
unclear [102, 107, 114]. cART suppresses viral replication to undetectable 
levels in the periphery; however, inflammation and viral reservoirs persist in 
the CNS [106, 115-117]. Additionally, ART compounds themselves may 
contribute to the pathogenesis of HAND [107]. ART-induced toxicity has been 
shown in primary rat cortical neurons [12, 31, 118].The integrated stress 
response (ISR) was identified as a mediator of ART-induced neurotoxicity by 
a subset of these compounds.  Further, ISR activation has been observed in 
neurons and astrocytes of HAND patients [12, 31, 118]. The ISR is 
cytoprotective and activated in response to extrinsic and intrinsic stressors 
such as viral infections, and accumulation of unfolded proteins in the 
endoplasmic reticulum (ER), respectively; however, if the stress is left 
unsolved this ultimately leads to cell death [53, 119, 120]. Furthermore, our 
group has previously reported that ART compounds ritonavir and lopinavir, 
inhibit oligodendrocyte maturation, in vitro; ritonavir also inhibited myelin 
protein production, in vivo [11]. We hypothesized that new frontline ART 
compounds from the INSTI class, elvitegravir (EVG) and raltegravir (RAL), will 
also affect oligodendrocyte maturation and/or survival, contributing to the 
myelin abnormalities observed in HAND patients. Here, we examine INSTIs, 
EVG and RAL, on primary rat oligodendrocyte precursor cell (OPC) 
maturation and survival using a well-established in vitro model [94, 119]. 
Moreover, we test the effect of EVG on remyelination following cuprizone-
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induced [77, 121, 122]. Finally, we show that the ISR mediates the effects of 
EVG in our in vitro oligodendrocyte maturation model. Our results support a 
role for INSTI, EVG, in myelin abnormalities seen in HAND patients and 
provides the first evidence to suggest the ISR as a mediating pathway that 
could be therapeutically relevant to these patients. 
 
2.3 Materials and Methods 
Chemicals and Reagents. The following antibodies used in this study were 
purchased from the indicated vendors: GeneTex (Irvine, CA): Aspartoacylase 
(ASPA; Cat# RRID: ); Wako (Osaka, Japan): ionized calcium binding adaptor 
molecule 1 (IBA1; Cat#  RRID: ); Invitrogen (Carlsbad, CA):  phospho-
eukaryotic initiation factor 2 alpha (p-eIF2α; Cat# 44-728G RRID: 
AB_1500038); Cell Signaling Technology (Beverly, MA): eukaryotic initiation 
factor 2 alpha (eIF2α; Cat# RRID:), phospho-eukaryotic initiation factor 2 
alpha (p-eIF2α; Cat# RRID:); BD Biosciences (San Jose, CA): platelet derived 
growth factor receptor alpha (PDGFRα, Ca# 556002 RRID: AB_396286); 
Sigma Aldrich (St. Louis, MO): alpha-tubulin (α-tubulin; Cat# T5168 RRID: 
AB_477579); Millipore (Temecula, CA): glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; Cat# MAB374 RRID: AB_2107445), neural/glia 
antigen 2 (NG2, Ca# AB5320 RRID: AB_11213678);  BioLegend (San Diego, 
CA): myelin basic protein (MBP; Cat# 808401 RRID: AB_2564741); 
Proteintech (Rosemont, IL): activating transcription factor 4 (ATF4; Cat# 
10835-1-AP RRID: AB_2058600), lamin B1 (Ca# 12987-1-AP RRID: 
AB_213690). Additional antibodies were: galactocerebroside (GalC) mouse 
hybridoma supernatant (GalC H8H9) (Ranscht et al., 1982), myelin basic 
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protein (MBP, rat hybridoma supernatant) and glial fibrillary acidic protein 
(GFAP) (kind gifts of Dr. Virginia Lee, University of Pennsylvania, 
Philadelphia, PA). The following chemical reagents used in the study were 
purchase from the indicated vendors: Sigma Aldrich (St. Louis, MO): poly-D-
lysine (PDL), biotin, dimethyl sulfoxide (DMSO), Triton X-100, Fast Green 
FCF, insulin, protease inhibitor cocktail, thyroxine (T4), lithium carbonate, 
luxol fast blue, cuprizone, bovine serum albumin (BSA); Alfa Aesar 
(Lancashire, United Kingdom): cresyl violet; Jackson Immunoresearch 
Laboratories (West Grove, PA): FITC-conjugated goat anti-mouse IgG3, 
rhodamine-conjugated goat anti-rat IgG; LiCOR (Lincoln, NE): Odyssey goat 
anti-mouse IRdye 800CW, goat anti-mouse IRdye 680RD, goat anti-rat IRdye 
800CW, goat anti-rat IRdye 680RD, goat anti- rabbit IRdye 800CW, goat anti-
rabbit IRdye 680RD; Toronto Chemicals (Toronto, Canada): elvitegravir; 
ASTA Tech (Bristol, MD): cobicistat; Invitrogen (Carlsbad, CA): 4%– 12% Bis-
Tris gradient gels, deoxyribonuclease 1 (DNase). R&D Systems (Minneapolis, 
MN): basic fibroblast growth factor (bFGF), platelet-derived growth factor-AA 
(PDGF-AA); PeproTech Inc. (Rocky Hill, NJ): neurotrophin-3 (NT3); Thermo 
Fisher Scientific (Waltham, MA): trypsin, B27 supplement, 
penicillin/streptomycin, Hank’s balanced salt solution (HBSS), neurobasal 
medium, Dulbecco’s modified Eagle’s medium and Ham’s F12 (DMEM/F12); 
Roche Diagnostics (Basel, Switzerland): biotin-16- dUTP; Vector Laboratories 
(Burlingame, CA): vectashield with 4',6-diamidino-2-phenylindole (DAPI); 
Biorad (Hercules, CA): precision plus protein kaleidoscope, tween-20, 
nitrocellulose membrane; Denville Scientific Inc. (Saint-Laurent, QC): HyBlot 
CL autoradiography film; Millipore (Temecula, CA): polyvinylidene fluoride 
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(PVDF) membrane. Tocris Bioscience (Bristol, UK): trans-ISRIB. Lonza 
(Walkersville, MD): L-glutamine.  
 
Preparation of primary rat oligodendrocyte precursor cell cultures. All 
experiments were performed in accordance with the guidelines set forth by 
The Children's Hospital of Philadelphia and The University of Pennsylvania 
Institutional Animal Care and Use Committees. Primary rat oligodendrocytes 
precursor cells (OPCs) were isolated from brains of postnatal day 1 Sprague 
Dawley rats (Charles River Laboratories, Wilmington, MA RRID: 
RGD_737891) and plated on T75 flasks [11]. We purified the OPCs using the 
“shake-off” method [123]. Briefly, once OPCs reached confluency on T75 
flasks, they were rotated on an orbital shaker set to 250 rpm and incubated 
overnight at 37°C. The following day, cells were filtered using a 20-µM nylon 
net (Merck Millipore, Darmstadt, Germany), followed by centrifugation at 1500 
rpm for 5 min at 4°C. The supernatant was discarded, and the pellet was 
resuspended in neurobasal medium (5 mL), then incubated in a 
bacteriological petri dish for 15 min at 37°C and 5% CO2. The supernatant is 
collected and centrifuged at 1500 rpm for 5 min at 4°C. The pellet was 
resuspended in growth media consisting of neurobasal media with B27 and 
growth factors: PDGF (2 ng/mL), NT3 (1 ng/mL) and FGF (10 ng/mL) and 
plated on 24-well plates with coverslips or 10 cm petri dishes. 
 
Drug Treatments. Primary rats OPCs were grown in 24-well plates with 
coverslips or 10 cm petri dishes, for immunocytochemistry and immunoblot, 
respectively, until they reached about 70% confluency. To differentiate the 
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cells into mature oligodendrocytes, growth medium was replaced with 
differentiation media consisting of 50% DMEM, 50% Ham’s F12, Pen/Strep, 2 
mM glutamine, 50 µg/mL transferrin, 5 µg/mL putrescine, 3 ng/mL 
progesterone, 2.6 ng/mL selenium, 12.5 µg/mL insulin, 0.5 µg/mL T4, 0.3% 
glucose, and 10 ng/mL biotin. Simultaneously, the cells were treated with 
vehicle (DMSO), raltegravir (300 nM, 3.0 µM or 10 µM), elvitegravir (350 nM, 
3.5 µM or 10 µM) or cobicistat (150 nM, 1.5 µM, 4 µM) for 72 hours, to allow 
differentiation to occur, before staining or protein collection [124]. Even though 
cobicistat is not active as an ARV, we examined the effect of cobicistat on 
oligodendrocyte maturation, in vitro, as it was used in our in vivo experiments 
to enhance administered elvitegravir concentrations. Pretreatments with 
Trans-ISRIB (5 µM) were 1 hour prior to elvitegravir (3.5 µM or 10 µM) 
treatment.  
 
Immunofluorescence. Primary OPC cultures were prepared and stained as 
follows: coverslips were removed from wells and rinsed with PBS; then they 
were incubated with primary antibody for immature oligodendrocyte marker, 
GalC, diluted 1:4 in DMEM/12, for 30 min at room temperature. Coverslips 
were rinsed with PBS and incubated coverslips in FITC-conjugated goat anti-
mouse secondary antibody, diluted at 1:200 in DMEM/F12, for 30 min at room 
temperature. Cells were fixed using 4% paraformaldehyde for 10 min then 
rinsed with PBS before incubation with a blocking/permeabilization solution 
containing 0.5% BSA and 0.1% Triton X-100 in PBS for 30 min. Cells were 
incubated in primary antibody for mature oligodendrocyte marker, MBP rat 
hybridoma supernatant, diluted 1:1 in PBS, for 30 min at room temperature. 
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Following a rinse with PBS, cells were incubated with rhodamine-conjugated 
goat anti-rat secondary antibody, diluted at 1:200 in PBS, for 30 min at room 
temperature. Cells were mounted on slides with vectashield mounting media 
containing DAPI (Vector Laboratories, Burlingame, CA). Cells were imaged 
using a Keyence BZ-X-700 digital fluorescent microscope (Keyence 
Corporation, Itasca, IL) affixed with UV, FITC, Cy3 and Cy5 filters. Images 
captured at 40x magnification were hand counted to quantify the number of 
immature and mature oligodendrocytes. Specifically, the number of immature 
and mature oligodendrocytes, identified as cells expressing GalC and MBP, 
respectively, was averaged across a total of 20 fields/coverslip with 2-4 
coverslips/treatment condition for each biological replicate.  
 
TUNEL Assay. To assess cells committed to apoptotic cell death, a TUNEL 
staining protocol, adapted from Gavrieli et al was used (Gavrieli et al., 1992). 
Cells were fixed with ice cold methanol for 10 min, washed with PBS, and 
permeabilized with 0.1% Triton X-100 and 0.5% BSA in PBS for 30 min. 
Positive control coverslips were generated during this time by incubating in 
DN buffer (30 mM Trizma base pH 7.2, 140 mM sodium cacodylate, 4 mM 
magnesium chloride, and 0.1 mM dithiothreitol) for 2 min, followed by DNase 
(1:200) in DN buffer for 10 min. All coverslips were washed with PBS, then 
placed in TDT buffer (30 mM Trizma base pH 7.2, 140 mM sodium 
cacodylate, 1 mM cobalt chloride) for 2 min. Cells were incubated for 1 hour at 
37°C with TdT and biotin-UTP in TDT buffer (6 uL of each in 1 mL TDT 
buffer). After a subsequent PBS wash, cells were placed in TB buffer for 15 
min (300 mM sodium chloride, 30 mM sodium citrate) and then a 2% BSA 
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solution for 30 min. Finally, cells were incubated with rhodamine-conjugated 
streptavidin for 20 min before a final PBS wash and mounting on slides with 
vectashield containing DAPI. Visualization and counting were performed as 
previously described [125]. 
 
RNA extraction and qPCR. The expression of MBP in oligodendrocyte 
cultures was quantified using quantitative reverse transcription polymerase 
chain reaction (RT-PCR). OPC cultures were grown on 100-mm dishes and 
harvested after 72-hour EVG treatment. RNA was extracted with Trizol, and 
RNA (5 μg) was converted to cDNA by the Invitrogen Superscript First-strand 
kit. Quantitative PCR was performed using Power SYBR Green, as previously 
described (Jensen et al., 2015). Samples were measured in triplicate for each 
experiment from 3 biological replicates (n = 3). Data were normalized using 
protein kinase gene 1 and analyzed according to the ΔΔCT method. Primer 
pairs obtained from Integrated DNA Technologies (Coralville, IA) for each 
gene are listed in Table 2. 
 
MBP Forward for rat 5’- TGA AAA CCC AGT AGT CCA C-3’ 
MBP Reversed for rat  5’- GGA TTA AGA GAG GGT CGT C-3’ 
PLP Forward for rat 5’-TAG GAC ATC CCG ACA AGT-3’ 
PLP Reversed for rat 5’-AAA CAG GTG GAA GGT CAT T-3’ 
Table2: Primers used for qPCR for MBP and PLP gene 
 
Immunoblotting. Whole cell extracts of primary rat oligodendrocyte cultures 
were prepared with cold cell lysis buffer (25 mM Tris (pH 7.4), 10 mM EDTA, 
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10% SDS, 1% Triton X-100, 150 mM NaCl containing protease and 
phosphatase inhibitor cocktails (PIs; Roche Diagnostics) followed by 
sonication and centrifugation at 10,000 rpm at 4°C for 30 min. Protein 
concentrations were determined by spectrophotometer ND-1000 from Thermo 
Fisher Scientific (Waltham, MA). Protein (7-20 µg) was loaded into each lane 
of 4% to 12% Bis-Tris gradient gels for separation. A broad-spectrum 
molecular weight ladder was run on each gel. After separation, proteins were 
transferred onto Immobilon-FL or nitrocellulose membranes and blocked in 
5% milk for 30 minutes at room temperature. Membranes were incubated 
overnight at 4°C with primary antibodies in TBST + 5% BSA. Primary 
antibodies to the following antigens were used: MBP (SMI-99, 1:1000 
dilution),  α-tubulin (1:10000 dilution), ATF4 (1:1000 dilution), pEIF2α (1:1000 
dilution, Cell Signaling), tEIF2α (1:1000 dilution),  Lamin B1 (1:1000 dilution) 
and GAPDH (1:60,000 dilution). Following three washes in TBST, membranes 
were incubated with corresponding antigen specific fluorescent probe-
conjugated secondary antibodies (1:10000 dilution) in TBST + 5% BSA. 
Membranes were visualized using an Odyssey Infrared Imaging System 
(LiCOR) or by film. Densitometric analysis of band intensities was conducted 
using the Odyssey Infrared Imaging System or by Fiji (NIH RRID: 
SCR_002285). All bands were normalized to the loading control, specified in 
each experiment.  
 
Nuclear/Cytoplasmic Fractionation. For examination of activating transcription 
factor 4 (ATF4) nuclear cytoplasmic fractionation was performed. Briefly, 3-4 
petri dishes of primary rat OPCs were stimulated to differentiate and treated 
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with vehicle (DMSO), EVG (3.5 µM) or positive control, thapsigargin (THAP, 
500 nM). After 24 hours, cells were rinsed thoroughly with PBS and incubated 
at 4°C on a shaker (150 rpm) in the presence of cytoplasmic buffer (250 µL, 
10 mmol/L HEPES, pH 7.9, 10 mmol/L KCL, 10 mmol/L EDTA, 1 mmol/L 
dithiothreitol, and 10% NP-40, supplemented with protease inhibitors) for 10 
min. Extracts were centrifuged at 12600 rpm for 3 mins, and cytoplasmic 
supernatants were collected. The pellets were washed with cytoplasmic buffer 
(500 µL) and centrifuged again at 12600 rpm for 3 min. The pellets were then 
resuspended in nuclear buffer (100 µL, 20 mmol/L HEPES, pH 7.9, 400 
mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L dithiothreitol, and 10% glycerol, 
supplemented with protease inhibitors) and incubated on an orbital shaker 
(200 rpm) at 4°C for 3 hours. Every 30 min the samples were vortexed at the 
highest setting for 10 sec. The nuclear supernatants were collected following 
centrifugation at 12600 rpm for 5 mins. All pellets were retained for potential 
analysis. Protein concentrations were determined the same as whole cell 
extracts (see above).  
 
Cuprizone Model and In-vivo Drug Treatments. All experiments were 
performed following the guidelines set by Children’s Hospital of Philadelphia 
Institutional Animal Care and Use Committee (IACUC) and University of 
Pennsylvania Institutional Animal Care and Use Committees.  Six to eight 
week old C57BL/6 female mice were used for the cuprizone demyelination 
model (Jackson Laboratories, PA). Mice were divided into two groups: control 
and cuprizone-treated. Each group was then divided further into untreated, 
vehicle (DMSO)-treated, EVG/COBI-treated, with 10 female mice in the 
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untreated group and 5 per group in the rest. Control mice received normal 
powdered food for five weeks, while the cuprizone-treated mice received 
0.25% cuprizone in their powdered food for five weeks. Both groups received 
normal food pellets during the last 3 weeks of the experiment. After 5 weeks 
of cuprizone feeding, 5 mice from each group, control and cuprizone were 
perfused, had brains removed and prepared for frozen section (see below) to 
determine to extent of the cuprizone lesion. At the same time point, other mice 
were implanted with IV cannula into the jugular vein and treated once daily 
with DMSO and/or EVG/COBI for the 3 week recovery period. For the 
implantation of the cannulas, sustained release buprenorphine (0.5-1.0 
mg/kg) was administered at subcutaneous injection before the start of 
surgery.  A ketamine/xylazine cocktail (80 and 12 mg/kg, respectively) was 
used to anesthetize the mice. A silastic IV cannula (CamCaths, Cambridge, 
UK) was inserted into the jugular vein, sutured in place using PERMA-HAND 
silk suture, (Ethicon Inc., Somerville, NJ) and mounted on the back of the 
mouse using a mesh back-mount. Over the course of the 3 week recovery 
period, mice were injected daily through the cannula with vehicle (DMSO) 
(5%), or EVG/COBI (65 mg/kg, diluted in DMSO).  
 
Immunohistochemistry. Following the 5 weeks cuprizone or control feeding 
period and the extra 3 weeks DMSO or EVG/COBI injections, mice were 
terminally anaesthetized with a ketamine/xylazine cocktail and intracardially 
perfused with cold PBS and cold 4% paraformaldehyde (PFA, pH 7.4). Whole 
brains were isolated, post-fixed in 4% PFA for 2 hours and then cryoprotected 
with 30% sucrose in PBS for at least 24 hours. Serial coronal tissue sections 
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were cut at 12μm on a cryostat (Leica Microsystems, Exton, PA) throughout 
the entire corpus callosum, collecting three sections per slide[124, 126].  
Mouse coronal tissue sections were stained as follows: we used ASPA (1:500 
dilution) for labeling mature oligodendrocytes, NG2 (1:200 dilution) for labeling 
of OPCs, GFAP (1:1 dilution) for labeling astrocytes and IBA1 (1:500 dilution) 
for labeling microglia. All primary antibodies were diluted in GFAP in Feltri 
block (20% FBS, 80% PBS, 0.02% BSA, 0.001% Triton X-100, 0.02% NaN3) 
and incubated overnight at 4°C.  Following a PBS wash, slides were 
incubated for 30 mins at room temperature in rhodamine red-conjugated, goat 
anti-rabbit antibody (1:200 dilution, diluted in PBS) to visualize ASAP, FITC-
conjugated, goat anti-rabbit antibody (1:200 dilution, diluted in feltri block) to 
visualize NG2, Cy5-conjugated, goat anti-rat antibody (1:200 dilution, diluted 
in PBS) to visualize GFAP, and FITC-conjugated, goat anti-rabbit antibody 
(1:200 dilution, diluted in feltri block) to visualize IBA1.  
For pEIF2α staining, we used a tyramide amplification system (Perkin Elmer) 
following overnight incubation at 4°C with the primary antibody (1:3000 
dilution, diluted in Feltri block, Invitrogen). Following a PBS wash, slides were 
incubated in biotin-conjugated, secondary antibody (1:600 dilution) for 30 
mins at room temperature and then incubated in Fluorescein (DTAF)-
conjugated Streptavidin (1:200 dilution, diluted in PBS) for 30 mins at room 
temperature (Jackson ImmunoResearch Laboratories). All slides were 
mounted in Vectashield with DAPI (Jackson ImmunoResearch Laboratories).  
To count cells from frozen sections, brains from at least three mice were used 
per variable. Digital images were taken at 20 X magnification from sections at 
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the level of the anterior part of the corpus callosum, counting five 150 m X 
150 m regions of interest per section, at least two sections per animal.  
 
Luxol fast blue (LFB) staining. Mouse brain section slides were stained with 
0.1% LFB, 0.1% Cresyl echt violet, and 0.05% lithium carbonate. The slices 
were dipped in 95% ethyl alcohol then incubated in LFB for 16-18 hours, 
followed by incubation in 95% alcohol for 2 minutes. The slides were then 
immersed in lithium carbonate solutions for another 2 minutes, followed by 
immersion in 70% ethyl alcohol for 30 sec. The slides were dipped quickly in 
water, and then incubated in Cresyl echt violt for 11 minutes at 56ºC. Finally, 
the slides were dipped in quick succession in 95% ethyl alcohol and xylene 
and then sealed with plastic covers using paramount.  
 
Statistical analysis. For all rat cell culture experiments, primary OPC cultures 
prepared from each litter represents an independent biological replicate, and 
were treated with vehicle or drug in the indicated combinations. An untreated 
condition (UT) was also included within each biological replicate, and all 
results were normalized to this UT value. Repeated measures analysis of 
variance (ANOVA) was used to analyze these data to account for inherent 
correlations present within a single biological replicate. Data were analyzed 
using Graphpad Prism statistical software (version 7.0; RRID: SCR_002798) 
and were graphically presented as fold change or percent total from UT +/- 
standard error of the mean (SEM), with the UT condition represented by a 
dotted line.  
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2.4 Results 
Elvitegravir reduces the number of immature and mature 
oligodendrocytes in vitro. Previously, our group has shown that ART 
compounds of the PI class, ritonavir and lopinavir, inhibit the maturation of 
oligodendrocytes, in vitro [11]. Using our well-established culture model [119], 
we examined whether INSTIs, elvitegravir (EVG) and raltegravir (RAL), 
inhibited oligodendrocyte maturation. EVG and RAL concentrations were 
based on reported plasma and cerebrospinal fluid (CSF) levels in humans, as 
measurements in human brain parenchyma have not been performed [127-
129].  
Clinically, EVG, is administered with cobicistat (COBI) because it is an 
inhibitor of cytochrome p450 enzymes in the liver, which metabolize EVG [44, 
129]. Thus, by combining EVG with COBI, lower concentrations of EVG can 
be given to patients, to reduce side effects, while still achieving therapeutically 
relevant concentrations of EVG in the body. Even though COBI is not active 
as an ARV, we examined the effect of COBI on oligodendrocyte maturation as 
it is administered with EVG in patients. Briefly, OPCs were placed in 
differentiation media and treated with therapeutically relevant concentrations 
of EVG (350 nM, 3.5 µM, 10 µM), RAL (300 nM, 3 µM, 10 µM), or COBI (150 
nM, 1.5 µM, 4 µM). After 72 hours, cultures were stained for transiently-
expressed lineage specific proteins: GalC and MBP for immature and mature 
oligodendrocytes, respectively [130-133]. Representative images of drug-
treated oligodendrocytes after 72 hours of differentiation showed dose-
dependent decreases in differentiation in EVG-treated cultures compared with 
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vehicle-treated cultures, but not RAL- or COBI-treated cultures (Figure 4A). 
GalC-positive and MBP-positive cell counts demonstrated a dose-dependent 
decrease of differentiation into immature and mature oligodendrocytes, 
respectively, in EVG-treated cultures compared with vehicle-treated cultures, 
but not following RAL or COBI treatment (Figure 4B,C). This effect is 
mediated at the transcriptional level since our qPCR result showed a dose 
dependent reduction in MBP mRNA in cells treated with EVG (Figure.5)  
Elvitegravir does not induce cell loss or apoptosis. In order to determine 
whether the decreased numbers of immature and mature oligodendrocytes 
observed following EVG treatment were due to inhibition of OPC maturation 
and not cell loss or apoptosis, we examined whether OPCs were dying  by 
four measures, 1) numbers of DAPI-positive cell counts, 2) A2B5-positive cell 
numbers and 3) number of terminal UTP Nick end labeling (TUNEL) assay 
positive cells, which stains double-stranded DNA breaks, an early step in 
apoptotic cell death, and 4) number of cells staining for propidium iodide, a 
DNA intercalating agent that only passes through the membrane of necrotic 
cells, thus labeling nuclei of dying cells. After 72 hours of maturation, the 
number of DAPI- A2B5- positive cells did not change following EVG, RAL or 
COBI treatment (Figure 6A,B). Additionally, there was no increase in TUNEL-
positive cells nor cells labeled with propidium iodide following EVG treatment 
(Figure 6C,D). DNase was used as a positive control for the TUNEL assay 
(Figure 6D). Together, these results suggest that EVG inhibits 
oligodendrocyte maturation in a dose-dependent fashion. 
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Elvitegravir treatment inhibits myelin protein production. Given that EVG-
treated cultures contained fewer GalC- and MBP-positive cells, as compared 
with vehicle control, we next examined whether this effect resulted in 
decrease myelin protein levels. The cultures were treated as previously for 72 
hours, protein was collected and processed for immunoblot analysis. The two 
doses of EVG (3.5 µM and 10 µM) resulted in a significant decrease in MBP 
levels when compared with vehicle (Figure 7A). In contrast, neither RAL nor 
COBI significantly altered MBP levels (Figure 7B,C). These data match that of 
the immunofluorescence results in Figure 4, with a large decrease in MBP-
positive cells and MBP protein levels observed at 3.5 µM and 10 µM 
concentrations of EVG. 
Elvitegravir-mediated inhibition of oligodendrocyte maturation is 
reversible. To determine if the effects of EVG were permanent, or if cells 
were capable of myelin protein production and localization once the drug was 
removed, we placed OPCs in differentiation media in the presence of 3.5 µM 
and 10 µM EVG and allowed 72 hours for maturation. At this time-point, a 
subset of cultures were washed and placed in drug-free differentiation media 
for an additional 24 hours. Cultures that underwent the drug washout period 
were stained for the same oligodendrocyte markers previously described and 
compared with cultures that did not undergo drug washout but were exposed 
to the same EVG treatments for 72 hours. As shown in Figure 4, 72 hour 
treatment with 3.5 µM EVG resulted in fewer GalC- and MBP-positive 
compared with vehicle; this effect was completely reversed after the removal 
of EVG (Figure 8B,C). Similarly, drug washout for 24 hours resulted in the 
reversal of reduced MBP expression levels following treatment with 3.5 µM 
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EVG as detected by immunoblotting (Figure 8D, E). In contrast, 24 hours after 
removal of the 10 µM concentration of EVG, the number of GalC- and MBP-
positive cells remained reduced (Figure 8B,C). Similarly, drug washout for 24 
hours did not rescue the reduction in MBP expression levels following 10 µM 
EVG treatment (Figure 8D,E).  
Administration of elvitegravir during recovery from cuprizone-induced 
demyelination inhibits remyelination. The process of remyelination occurs 
when mature oligodendrocytes regenerate new myelin sheaths around axons 
of neurons in the CNS [111, 134]. Remyelination can restore conduction 
properties to axons leading to restoration of neurological function [111, 134]. 
There is persistent myelin abnormalities seen in HAND patients, regardless of 
the administration of cART [108-110]. In order to examine the effect of EVG, 
on remyelination, we used a widely implemented toxin-induced demyelination 
model. The copper chelator, cuprizone (bis-cyclohexanone-oxaldihydrazone), 
is combined into the feed of mice for five weeks, and targets mature 
oligodendrocytes to die [77, 121, 122], creating a consistent demyelination 
best seen in the corpus callosum, the largest white matter tract in the mouse 
brain [77, 121, 122]. In addition, this demyelination is accompanied by the 
accumulation of microglia and astrocytes [77]. Removal of cuprizone from the 
feed permits remyelination over the course of three weeks [77, 121, 122] 
During the three-week recovery period following cuprizone-induced 
demyelination. EVG/COBI was injected at a dose found to result in similar 
plasma levels as those reported in human patients [135, 136]. In a separate 
experiment, we compared two routes of administration of the drug: IV 
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(Intravascular) or IP (Intraperitoneal). Plasma levels resulting from IV injection 
were closer to the human plasma level (Table 3) [135].  
 
Treatment 
Route of 
administration 
Time point 
Average Plasma 
Conc. in µg/ml 
 
N# 
DMSO IP 5 hours 0 2 
EVG/COBI IP 5 hours 5.35 1 
DMSO IV 5 hours 0 3 
EVG/COBI IV 5 hours 13.47 2 
DMSO IP 7 days 0 2 
EVG/COBI IP 7 days 0.19 2 
DMSO IV 7 days 0 3 
EVG/COBI IV 7 days 0.845 2 
Table 3: A comparison between IP and IV route of adminstration: mice were 
treated with the vehicle (DMSO) with or without EVG/COBI daily for 7 days. 
Plasma samples were taken 5 hours after the injection of drug on day 1 and 7 
and analyzed by mass spectometry.  
EVG was administered daily via IV jugular vein cannula; COBI was co-
administered with EVG in order to boost EVG concentrations, while control 
animals received the vehicle, DMSO (Figure 9). After 5 weeks of cuprizone 
feeding or at the end of the three-week recovery period, brains were 
processed for frozen sections and luxol fast blue (LFB) staining was used to 
label myelin (Figure 9). The cuprizone-treated mice showed the characteristic 
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decrease in myelin in the center of the corpus callosum following 5 weeks of 
cuprizone ingestion and the expected complete remyelination after three 
weeks recovery (Figure 9). However, mice treated with EVG and COBI during 
recovery from cuprizone had significantly less myelin compared with mice that 
remained untreated during the 3 week recovery or mice treated with DMSO 
during the recovery from cuprizone exposure (Figure 9). Interestingly, there 
were no gross changes in myelin in the corpus callosum in EVG/COBI-
injected mice in the absence of cuprizone when compared with all other 
control groups (Figure 9).  
To further confirm the effect of EVG on remyelination, we stained mouse 
sections from all experimental groups for the mature oligodendrocyte marker, 
ASPA [137, 138]. As expected, there were significantly fewer ASPA positive 
cells in the 5 week cuprizone-exposed mice compared with control mice; after 
the three-week recovery period, the number of ASPA positive cells in 
cuprizone exposed mice permitted to recover for 3 weeks were no different 
from control levels (Figure 10). In contrast, there were fewer ASPA positive 
cells in the corups callosum of mice treated with EVG/COBI following the 3 
week recovery from cuprizone exposure compared with control mice, DMSO-
injected cuprizone recovery mice, or untreated cuprizone recovery mice 
(Figure 10). These data are consistent with LFB data shown in Figure 5 and 
suggest that EVG inhibits remyelination of the corpus callosum.  
While the precise mechanisms of cuprizone-mediated demyelination are 
unclear, several studies have demonstrated that anti-inflammatory agents can 
attenuate cuprizone-induced damage to the corpus callosum and prevent 
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demyelination [139]. To determine whether astrogliosis and/or microgliosis 
persist during EVG/COBI treatment during recovery from cuprizone treatment, 
we measured the effect of EVG on the inflammatory environment during 
remyelination. We stained mouse sections for astrocytes and microglia using 
GFAP and IBA1, respectively (Figure 11). We observed an increase in GFAP 
and IBA1 fluorescent intensity in 5 week cuprizone-treated mice which 
subsequently decreased to the levels of control mice after three weeks of 
recovery. However, in the EVG/COBI-injected cuprizone recovery mice GFAP 
and IBA1 fluorescent intensity were still increased when compared with 
untreated cuprizone recovery and DMSO-injected cuprizone recovery mice 
(Figure 11).  
Our data suggest that EVG inhibits differentiation of OPCs into mature 
oligodendrocytes in vitro. If the same were occurring in vivo, we would expect 
an increase in OPCs or immature oligodendrocytes in the corpus callosum of 
cuprizone-treated mice receiving EVG/COBI during recovery. To determine 
whether OPCs were increased in the corpus callosum of mice given 
EVG/COBI during the 3 week recovery from cuprizone, we stained mouse 
sections for NG2. Consistent with previous results, we observed an increase 
in the NG2 fluorescent intensity in 5 week cuprizone-treated mice [140]; 
however, the increase in NG2 positive was reversed to the level of untreated 
mice after three weeks of recovery. In contrast, in the EVG/COBI-injected 
cuprizone recovery mice, NG2 fluorescent intensity was still increased when 
compared with untreated cuprizone recovery and DMSO-injected cuprizone 
recovery mice (Figure 12).  
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The integrated stress response (ISR) partially mediates elvitegravir-
driven inhibition of oligodendrocyte maturation, in vitro. Previous studies 
have shown that EVG induces neuronal damage via induction of the ISR [12]. 
ISR induction is known to halt oligodendrocyte differentation [141]. To 
determine whether EVG is affecting OPC maturation via ISR induction, , we 
examined whether ISR inhibitor, trans-ISRIB, alleviated the observed EVG-
induced OPC maturation defect in vitro [142]. Representative images show 
that cultures pretreated with trans-ISRIB one hour prior to EVG (3.5 µM) 
treatment had increased immature and mature oligodendrocytes, identified as 
GalC- and MBP-positive cells, compared with cultures not pretreated with 
ISRIB (Figure 13A). These observations were confirmed by counting the 
number of GalC positive immature and MBP  positive mature 
oligodendrocytes in cultures pretreated with trans-ISRIB as compared with 
cultures not pretreated with trans-ISRIB (Figure 13B,C). Examination of MBP 
protein expression levels in which cultures were pretreated with ISRIB 
demonstrated maintenance of MBP protein levels compared with cultures not 
pretreated with trans-ISRIB (Figure 13D,F). Notably, cultures pretreated with 
trans-ISRIB prior to EVG (10 µM) treatment, resulted in immature and mature 
oligodendrocyte numbers and expression of MBP comparable to cultures not 
pretreated with trans-ISRIB (Figure 13).  
2.5 Discussion 
The introduction of cART has changed the landscape of HIV/AIDS, viral 
suppression results in fewer patients progressing to AIDS and expansion of 
the lifespan of HIV-positive individuals. However, given the persistence of 
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HAND despite of cART administration, a better understanding of cART side 
effects is necessary as patients now remain on cART regime for the entirety 
of their increased lifespans. Specifically, the new class of INSTIs require close 
examination as their use worldwide continues to grow.  
In the present study, we investigated the effects of front line ARV class 
INSTIs, EVG and RAL, on oligodendrocyte maturation and myelination. 
Maturation and myelination inhibition was induced only by EVG. Furthermore, 
our in vitro and in vivo studies showed EVG activated ISR in 
oligodendrocytes. Pharmacological attenuation of the ISR with trans-ISRIB, 
protected against EVG-induced oligodendrocyte maturation inhibition, in vitro. 
Despite being in the same class of ARV agents, EVG caused dose-dependent 
inhibition of oligodendrocyte maturation whereas RAL did not. This within-
class difference was dramatic as EVG at 3.5 µM and 10 µM induced a 50% 
and 95% decrease in GalC- and MBP-positive cells, respectively, whereas 
RAL, at similar doses and time course, had no effect. Moreover, the 
immunoblot results corroborated the immunocytochemistry as MBP 
expression was dramatically decreased with 3.5 µM and 10 µM EVG 
treatment whereas RAL had no effect. These data provide novel, compelling 
evidence for EVG-induced oligodendrocyte maturation defects. Furthermore, 
these data add to previous studies showing similar differential effects of 
INSTIs, EVG and RAL, in vitro, albeit in neurons [12, 143]. Importantly, our 
observations regarding EVG and RAL highlight critical differences in the 
effects on oligodendrocyte maturation within each ARV class. These studies 
could be helpful to clinicians when deciding which ARV drug to administer, 
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especially in younger patients that are still developing myelin and might be on 
cART for decades. 
We utilized the cuprizone demyelination model in order to examine the effects 
of EVG on remyelination in vivo. Cuprizone-induced demyelination is widely 
utilized to study demyelination/remyelination not caused directly by 
inflammation, as it leads to the specific degeneration of oligodendrocytes in 
the corpus callosum [77, 121, 122]. Using this model to demyelinate the 
corpus callosum, we showed that daily administration of EVG/COBI during the 
3-week recovery period, following cuprizone ingestion, resulted in diminished 
remyelination and decreased mature oligodendrocytes via LFB staining and 
ASPA positive cell counts, respectively plus an increase in the NG2 positive 
OPCs which correspond with the in vitro finding in which EVG/COBI 
prevented OPCs from maturation. Notably, there was no change in LFB 
staining and ASPA positive cell counts in control mice injected daily with 
EVG/COBI suggesting that EVG induces inhibition of differentiation in OPCs, 
but has no affect on already mature oligodendrocytes. There are limitations to 
these data as there could be some additive affect of cuprizone, itself, in 
EVG/COBI-injected cuprizone recovery mice. Thus, these data need to be 
interpreted thoughtfully as cuprizone-induced demyelination does not reiterate 
the white matter loss and abnormalities observed in HAND patients. This 
findings highlights the need for mouse models of HIV infection that 
recapitulate HIV persistence in the ART era as well as the myelin irregularities 
observed in HAND patients [144, 145].  
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An additional concern about the relevance of these findings is whether the 
doses of these observed effects with EVG are comparable to the doses 
observed in patients. Doses were selected to cover a wide range of 
concentrations relevant to the plasma and CSF concentrations observed in 
patients [44, 129, 146]. It is still unclear how these doses relate to levels of 
ARV drugs present in the brain parenchyma and some studies have shown 
that CSF drug concentrations may not accurately reflect this concentration 
[147]. As there is a focus on improving CNS penetration of ARV agents, it will 
become even more important to understand the potential side effects of such 
drugs at higher concentrations.  
In addition to characterizing the effects of EVG and RAL on oligodendrocyte 
maturation, we identified a potential mechanism that mediates this effect. We 
have previously shown evidence for ISR activation in neurons and astrocytes 
of HAND patients as well as in neurons in culture treated with different 
classes of ARV compounds[12, 31, 118, 148]. Furthermore, there is evidence 
for ISR activation in oligodendrocytes in other neuroinflammatory disease 
models such as multiple sclerosis [120, 149, 150]. Since there are multiple 
kinases by which to activate ISR, we examined the convergent upstream 
product, pEIF2α. The effects of ISR inhibitor, trans-ISRIB, were dose specific 
as well. Trans-ISRIB, mediated oligodendrocyte maturation rescue in cultures 
pretreated with trans-ISRIB, prior to EVG (3.5 µM) treatment whereas 
pretreatment with trans-ISRIB, prior to EVG (10 µM) did not result in rescue of 
oligodendrocyte maturation. The effect of EVG at 3.5 µM was reversible, as 
cells matured following drug removal, with GalC- and MBP-positive cells and 
MBP protein expression resembling controls after 24 hours. However, the 
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effect of EVG at 10 µM was not reversible. Taken together, these data 
suggest the cellular stress induced in oligodendrocyte in response to 10 µM 
EVG treatment is distinct from 3.5 µM EVG and ultimately the cell may be 
targeted for death rather than survival, although it is possible that there is 
more than one mechanism that mediates the differentiation defect of EVG on 
maturing OPCs. Neither dose of EVG led to detected increase in apoptotic 
cell death, identified as TUNEL-positive cells. However, after 72 hours 
treatment with EVG (10 µM) there was a small decrease in cell viability, 
identified as cells positive for propidium iodide which suggests necrotic cell 
death.  
In summary, these data add to a growing body of evidence that suggest a role 
for cART-mediated persistence of HAND. Specifically, these data support a 
role for cART-mediated persistence of white matter abnormalities observed in 
HAND individuals. Furthermore, we implicate the ISR as a potential 
contributing pathway in EVG-induced oligodendrocyte maturation defects. In 
addition to the development of new therapeutics with fewer deleterious side 
effects, we must consider adjunctive therapies designed to alleviate neuronal 
dysfunction and preservation of myelin formation and maintenance. 
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2.6 Figures:  
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Figure 4: INSTI EVG inhibits oligodendrocyte differentiation, whereas RAL 
does not. Primary rat cells (OPCs) plated on coverslip were put into 
differentiation media and treated with vehicle (DMSO), EVG (350nM, 3.5µM, 
and 10µM), RAL (300nM, 3µM, and 10µM), COBI (150nM, 1.5µM, and 4µM). 
After 72 hours, cells were fixed and stained with antibody to myelin basic 
protein (MBP), antibody to galactocerebroside (GalC), and DAPI as shown. A) 
There was a dose dependent reduction in GalC positive cells in the cells 
treated with EVG. B) Quantification of the GalC positive oligodendrocytes; 
significant dose dependent reduction in the GalC positive cells was observed 
in the EVG treated cells but not RAL nor COBI. C) Quantification of the MBP 
positive oligodendrocytes; significant dose dependent reduction in the MBP 
positive cells was observed in the EVG treated cells but not RAL nor COBI. 
Graphic represent fold changes in MBP and GalC, N=3, one-way ANOVA, # 
P<0.0001.  
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Figure 5: Effect of elvitegravir on MBP mRNA expression. Primary rat cells 
(OPCs) were put into differentiation media and treated with vehicle (DMSO) 
without or with elvitegravir at different dosages (3.5µM, and 10µM). A 
significant dose dependent reduction of mRNA expression level was identified 
at both 3.5µM and 10µM.  One way ANOVA, N=3, # P<0.0001  
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Figure 6: Antiretrovirals do not alter oligodendrocyte precursor cell (OPC) 
number nor induce apoptosis. Terminal deoxynucleotidyl transferase (TdT) 
dUTP Nick-End Labeling (TUNEL Assay), cell viability using propidium Iodide, 
and cell counts using A2B5 and DAPI stains were used to determine if the 
drugs cause a decrease in the overall number of oligodendrocyte lineage 
cells. None of the used drugs causes a significant decrease in cell number or 
an increase in apoptosis. One way ANOVA, N=3, #P<0.0001. 
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Figure 7: EVG but not COBI or RAL reduces MBP expression levels 
inoligodendrocytes. Primary rat cells (OPCs) were put into differentiation 
media and treated with vehicle (DMSO), EVG (350nM, 3.5µM, and 10µM), 
RAL (300nM, 3µM, and 10µM), COBI (150nM, 1.5µM, and 4µM). After 72 
hours, cell lysates were collected in order to measure protein expression. A) 
Quantification of MBP protein level for OPCs treated with elvitegravir. MBP 
expression level in untreated cells were compared to cells treated with DMSO 
with or without EVG at different doses (350nm, 3.5µM, and 10µM). Dose 
dependent decreases in the MBP protein levels were observed at 3.5µM and 
10µM, B) Quantification of MBP protein level of OPCs treated with RAL. MBP 
expression levels in untreated cells were compared to OPCs treated with 
DMSO with or without RAL at different doses (300nM, 3µM, and 10µM). No 
significant reduction was observed in the MBP protein level. C) Quantification 
of MBP protein level of OPCs treated with COBI. MBP expression levels in 
untreated cells were compared to OPCs treated with DMSO with or without 
cobicistat at different doses (150nM, 1.5µM, and 4µM). No significant 
reduction was observed in the MBP protein level. One way ANOVA, N=3, # 
P<0.0001  
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Figure 8: EVG inhibition of differentiation is reversible. A) Oligodendrocyte 
precursor cells (OPCs) were treated with vehicle (DMSO) and/or EVG (3.5µM, 
10µM) at the time of differentiation. After 72 hours, the washout group 
received new differentiation mediµM without EVG and was allowed to further 
mature for 24 hours. The cells were fixed and stained for GalC, MBP and 
DAPI. The inhibitory effect of EVG effects on GalC and MBP expression was 
reversible at 3.5µM but not 10µM. B) MBP protein level; (OPCs) were treated 
with vehicle (DMSO) and/or EVG (3.5µM, 10µM) at the time of differentiation. 
After 72 hours, the washout group received new differentiation medium 
without elvitegravir and was allowed to further mature for 24 hours. MBP 
levels were increased following washout in cells treated with 3.5µM 
elvitegravir but not 10µM. One-way ANOVA, N=3, one-way repeated 
measures ANOVA, @ P =0.002, & P<0.0001. 
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Figure 9: EVG inhibits remyelination in the cuprizone model of 
demyelination/remyelination. Six to eight week old C57BL/6 female mice were 
divided into two groups. The 1st group received control diet throughout the 
whole experiment, the 2nd group received 0.25% cuprizone in their diet for the 
1st 5 weeks of the experiment then control diet without cuprizone for a three 
week recovery period. Within each of these groups, subgroups were as 
follows: mice euthanized at 5 weeks to see the lesion, mice with or without 
cuprizone for 5 weeks and no other additives at the 8 week time point, mice 
given the vehicle DMSO for the 3 week recovery period, mice given 
elvitegravir/cobicistat in DMSO for the 3 week recovery period. Luxol Fast 
Blue (LFB) staining was performed on cryopreserved brain sections at the 
level of the corpus callosum.The lesion in the corpus callosum is clearly 
visible in the 5 week cuprizone group as compared with controls. This lesion 
is remyelinated after three weeks. However, the group of mice that were fed 
cuprizone and then received EVG/COBI during the 3 weeks recovery 
continued to exhibit a lack of myelin when compared to the other group. Semi-
quantification of demyelination by blind examiner scoring (3= intact myelin 
and 0=complete demyelination).[140, 151] . One way ANOVA, N=5, @ CUPZ 
ART compared to 5 Week CTL p = < 0.0001, & Cupz ART Compared to 8 
Weeks CTL p = < 0.0001, # Cupz ART compared to CTL DMSO p = < 0.0001, 
% Cupz ART compared to CUPZ UT p = < 0.0001, *CUPZ art compared to 
CUPZ DMSO p = < 0.0001 
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Figure 10: ASPA positive oligodendrocytes remain decreased in animals after 
3 weeks of EVG treatment during recovery from cuprizone intoxication as 
compared with cuprizone-only treated animals. Six to eight week old C57BL/6 
female mice were divided into two groups. The 1st group received control diet 
throughout the whole experiment, the 2nd group received 0.25% cuprizone in 
their diet for the 1st 5 weeks of the experiment then control diet without 
cuprizone for a three week recovery period. Within each of these groups, 
subgroups were as follows: mice euthanized at 5 weeks to see the lesion, 
mice with or without cuprizone for 5 weeks and no other additives at the 8 
week time point, mice given the vehicle DMSO for the 3 week recovery 
period, mice given elvitegravir/cobicistat in DMSO for the 3 week recovery. 
Cryosections of mouse brain at the level of the corpus callosum were stained 
with antibody to ASPA which labels oligodendrocyte cell bodies. The number 
of the ASPA positive cells were normalized to DAPI positive cells. There were 
no significant differences between the group of mice received normal diet plus 
EVG with the group of mice received normal diet or normal diet plus vehicle. 
The group of mice received cuprizone in their diet followed by EVG during the 
recovery period showed a significant reduction in the number of ASPA 
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positive cells when compared to mice had cuprizone in their diet then normal 
diet or normal diet plus vehicle during the recovery period. One way ANOVA, 
N=3, & Cupz ART Compared to CTL UT p = < 0.0001, # Cupz ART compared 
to CTL DMSO p = < 0.0001, % Cupz ART compared to CUPZ UT p = < 
0.0001, * CUPZ art compared to CUPZ DMSO p = < 0.0001 
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Figure 11: EVG treated mice have glial activation in the corpus callosum. Six 
to eight week old C57BL/6 female mice were divided into two groups. The 1st 
group received control diet throughout the whole experiment, the 2nd group 
received 0.25% cuprizone in their diet for the 1st five weeks of the experiment 
then control diet without cuprizone for a three week recovery period. Within 
each of these groups, subgroups were as follows: mice euthanized at 5 weeks 
to see the lesion, mice with or without cuprizone for 5 weeks and no other 
additives at the 8 week time point, mice given the vehicle DMSO for the 3 
week recovery period, mice given EVG/COBI in DMSO for the 3 week 
recovery. (A) Labeling for astrocytes (GFAP) and microglia (IBA1) shows an 
increase in both in the 5 week cupiraozne group and the group treated with 
EVG/COBI during the recovery period. (B) This was analyzed by intergrated 
intensity measurements. N=5, one-way ANOVA, for GFAB; @CUPZ ART 
compared to 5 Week CTL p = 0.004, & Cupz ART Compared to CTL 8 Weeks 
CTL p = < 0.0001, #Cupz ART compared to CTL DMSO p = 0.0003, %Cupz 
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ART compared to CUPZ UT p = 0.0036, * CUPZ art compared to CUPZ 
DMSO p = 0.0001. For IBA1; @Cupz ART Compared to CTL 5 wks, p = 
0.0003, & Cupz ART Compared to 8 weeks CTL p = 0.0002, # Cupz ART 
Compared to CTL DMSO p = 0.0001, %Cupz ART Compared to CUPZ UT p 
= 0.0037, *Cupz ART Compared to CUPZ DMSO p = 0.0057 
  
  
70 
Figure 12: EVG treated mice shows an increase in NG2 positive OPCs in the 
corpus callosum. Six to eight-week-old C57BL/6 female mice were divided 
into two groups. The 1st group received control diet throughout the whole 
experiment, the 2nd group received 0.25% cuprizone in their diet for the 1st five 
weeks of the experiment then control diet without cuprizone for a 3 weeks 
recovery period. Within each of these groups, subgroups were as follows: 
mice euthanized at 5 weeks to see the lesion, mice with or without cuprizone 
for 5 weeks and no other additives at the 8 weeks, mice given the vehicle 
DMSO for the 3 weeks recovery period, mice given EVG/COBI in DMSO for 
the 3 weeks recovery. An integrated intensity shows a sustained increase in 
the NG2 positive OPCs in the EVG/COBI-injected cuprizone recovery mice 
compared with untreated cuprizone recovery and DMSO-injected cuprizone 
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recovery mice. ANOVA, N=3, one-way ANOVA, @ EVG/COBI injected 
cuprizone compared to 5 weeks control P<0.0001, & EVG/COBI injected 
cuprizone compared to control DMSO P=0.0002, # EVG/COBI injected 
cuprizone compared to control injected EVG/COBI P<0.0001, % EVG/COBI 
injected cuprizone compared to DMSO injected cuprizone P<0.0001, * 
EVG/COBI injected cuprizone compared to 8 weeks recovery P<0.0001. 
  
  
72 
Figure 13: An eIF2α inhibitor (TRANS-ISRIB) rescued oligodendrocytes 
maturation in cells treated with EVG in-vitro. Primary rat cells (OPCs) plated 
on coverslip were put into differentiation medium and treated with vehicle 
(DMSO), Elvitegravir 3.5µM with or without TRANS-ISRIB. After 72 hours in 
differentiation medium, cells were fixed and stained with antibodies to GalC 
and MBP as well as DAPI as shown in A). B) Significant increase in the 
number of GalC positive cells was noted when cells were treated with 
elvitegravir plus TRANS-ISRIB at 3.5µM compared to cells treated with 
elvitegravir without TRANS-ISRIB. C) Significant increase in the number of 
the MBP positive cells was noted when cells were treated with elvitegravir at 
3.5µM when compared to cells treated with elvitegravir without TRANS-ISRIB. 
D) TRANS-ISRIB rescued MBP protein levels in cell treated with elvitegravir 
at 3.5µM, the result was normalized to loading control and to the untreated 
group, one-way repeated measures ANOVA, N=3, one way ANOVA, # P 
<0.05.  
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CHAPTER3: Effects of HIV anti-retroviral drugs on oligodendrocyte 
differentiation via the SREBP1 pathway: 
3.1 Abstract: 
Despite effective viral suppression and decreased mortality rate through 
combined antiretroviral therapy (cART), approximately half of HIV-positive 
patients on ART have HIV-associated neurocognitive disorder (HAND). A 
consistent finding revealed in studies of antiretroviral-treated HIV-positive 
patients is persistent white matter and myelin abnormalities. Myelin is the 
plasma membrane of oligodendrocytes and is crucial for rapid signal 
transduction and axonal maintenance of central nervous system (CNS) axons. 
A reduction in the amount of myelin contributes to neurocognitive dysfunction. 
Our lab has shown that differentiation of oligodendrocyte precursor cells 
(OPCs) is negatively affected by ART, but the mechanism behind this is still 
not clear. In this study we focused on RIT, a protease inhibitor used in 
conjunction with other drugs to improve pharmacokinetics of the compound. In 
the plasma, it increases the levels of both triglycerides and cholesterol due to 
increasing both fatty acid and cholesterol synthesis in the adipose tissue of 
the liver by activating a master lipid metabolism gene: the sterol regulatory 
element-binding protein (SREBP). Additionally, it has been shown that 
SREBP1 plays a major role in differentiation of oligodendrocytes and inhibiting 
SREBP activation results in a significant reduction in the number of mature 
oligodendrocytes in a differentiation paradigm in vitro. We hypothesize that 
changes in oligodendrocyte maturation due to RIT, are regulated by the 
SREBP1 pathway. We investigated both SREBP1 and three lipid enzymes in 
oligodendrocytes treated with RIT using an in-vitro model of primary 
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oligodendrocyte precursor cells from rats to understand the mechanism by 
which RIT inhibits oligodendrocyte differentiation. Our data show that 
treatment of oligodendrocyte progenitor cells in culture with RIT at the point of 
differentiation increased protein levels of SREBP1 and increased protein 
levels of Fatty Acid Synthase, a precursor for palmitate synthesis. Mass 
Spectometry of cell lysates reveals an increase in both newly made 
cholesterol and newly made palmitate in the RIT treated cells. These findings 
suggest that SREBP pathway is important regulator for oligodendrocyte 
maturation and that disruption of their activity may affect oligodendrocytes 
maturation myelination. 
 
3.2 Introduction: 
Cerebral white matter consists largely of densely packed oligodendrocytes 
that myelinate the neuronal axons. Oligodendrocytes are one of four glial cells 
present in CNS and form 5-8% of the total glial cells in the CNS[92]. These 
cells produce myelin, the lipid sheath that wraps and insulates axons and 
serves to increase the conductivity of the electrical impulses. The myelin 
membrane is apoprximately 70% lipid and during maturation and myelination, 
oligodendrocytes elaborate tremendous amounts of cellular membrane highly 
enriched in lipids. In addition, multiple proteins specific for myelin such as 
proteolipid protein (PLP) and myelin basic protein (MBP) are also generated 
and have their specific locations among the lipids in the myelin membrane 
[152]. One of the regulators of lipid metabolism in cells is Sterol Regulatory 
Element-binding Proteins (SREBPs) family (Figure 14). SREBPs are basic 
helix-loop-helix-leucine zipper transcription factors. The SREBP family is a 
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master regulator of cellular lipid metabolism, composed of three subgroups,  
SREBP1a, SREBP1c and SREBP2. In general, SREBP1a is important 
activator of all SREBP genes, involving synthesis of cholesterol, fatty acids, 
and triglycerides. While, SREBP1c is required for fatty acid synthesis and 
SREBP2 governs expression of enzymes that regulate synthesis of 
cholesterol. SREBP proteins are synthesized in the endoplasmic reticulum as 
a precursor protein. Various stimuli such as the cellular concentration of sterol 
regulate the cleavage of the membrane-bound precursor to be released as 
the mature nuclear form. The SREBP cleavage activating protein (SCAP), 
another ER membrane-embedded protein binds to SREBP at low 
concentration of cholesterol and transports it to Golgi apparatus. However, 
when cholesterol levels are high, oxysterol-binding Insigs (Insulin induced 
gene) induce a tight interaction with cholesterol-binding SCAP and prevent 
movement of the SREBP/SCAP complex to the Golgi blocking SREBP 
processing and activity [153, 154]. We have previously shown that SREBP is 
important for the differentiation of oligodendrocytes from the precursor stage 
to the mature stage and inhibition of SREBP transport to the nucleus inhibited 
process extension and expression of MBP [11, 85]. We hypothesize that 
oligodendrocytes treated with RIT induce SREBP expression leading to 
increased levels of cholesterol and fatty acids in these cells[155] and this 
impalance in cholesterol and fatty acids, in turn, inhibits differentiation of 
oligodendrocytes.  
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3.3 Material and Methods: 
All experiments were performed following the guidelines set by Children’s 
Hospital of Philadelphia Institutional Animal Care and Use Committee 
(IACUC) and University of Pennsylvania Institutional Animal Care and Use 
Committees. 
Chemical Reagents: 
Mouse monoclonal anti-α-tubulin antibody (T5168), biotin, dimethyl sulfoxide 
(DMSO), fast green FCF, insulin, protease inhibitor cocktail, thyroxine (T4) 
from (Sigma Aldrich, St. Louis, MO). (Jackson Immunoresearch Laboratories, 
West Grove, PA): FITC- conjugated goat anti-mouse IgG3, Rhodamine-
conjugated goat anti-rat IgG. (LiCOR, Lincoln, NE): Odyssey goat antimouse 
IRdye 800CW, goat antimouse IRdye 680RD, goat antirat IRdye 800CW, goat 
antirat IRdye 680RD, goat anti- rabbit IRdye 800CW, and goat antirabbit 
IRdye 680RD were from (Jackson Immunoresearch Laboratories, West 
Grove, PA). (Chemicon International, Temecula, CA) provided mouse 
monoclonal anti- glyceraldehyde 3-phosphate dehydrogenase antibody 
(GAPDH, MAB374). (Covance Laboratories, Conshohocken, PA) provided 
mouse monoclonal anti-MBP (SMI-99). B27 supplement, 4%– 12% Bis-Tris 
gradient gels, Dulbecco’s modified Eagle’s medium (DMEM), DMEM/F12, 
deoxyribonuclease 1 (DNase), Ham’s F12, L-glutamine, Hank’s balanced salt 
solution, neurobasal medium, and penicillin/streptomycin were from Life 
Technologies (Carlsbad, CA). (R&D Systems, Minneapolis, MN) was the 
source of basic fibroblast growth fac- tor (bFGF) and platelet-derived growth 
factor -AA (PDGF-AA). (Roche Diagnostics, Basel, Switzerland) supplied 
biotin-16- dUTP. Vectashield with 4',6-diamidino-2-phenylindole (DAPI) was 
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from (Vector Laboratories, Burlingame, CA). anti-galactocerebroside mouse 
hybridoma supernatant (GalC H8H9), [131] anti-GFAP mouse hybridoma 
supernatant, anti-MBP rat hybridoma supernatant (gift of Virginia Lee, 
University of Pennsylvania, Philadelphia, PA). SREBP1, and HMGCR from 
(Santa Cruz Biotechnology, Dallas, TX), FASN and ACC from (Cell signaling, 
Danvers, MA). 
 
Primary cerebral cortex oligodendrocytes cultures 
Primary oligodendrocytes precursor cells (OPCs) were collected from post-
natal day 1 rats (Sprague Dawley rats, Charles River Laboratories, Malvern, 
PA) with modification of the previously published techniques.[119] To purify 
the oligodendrocytes cultures, a shake-off technique was performed at 7-8th 
day following the prep. For the shake-off procedure,  T75 flasks were placed 
in the shaker incubator at 250 rpm overnight. The following day, cells were 
filtered through 20µM nylon filter (Merck Millipore, Darmstadt, Germany), 
followed by 5 minute centrifugation at 1500 rpm. The supernatant was 
discarded and the pellet resuspended into 5ml of neurobasal medium and 
incubated in bacteriological petri dish for 15 minutes at 37C and 5% CO2, 
then centrifuged  again at 1500rpm for 5 minutes to collect the medium, and 
the pellets are placed into growth medium. After purification, OPCs were 
grown using neurobasal medium with B27 with the addition of growth factors 
including bFGF, PDGF-AA, and neurotrophin-3 (NT3) till reach 70-75% 
confluency. TO differentiate the OPCs ot mature oligodendrocytes,  growth 
factors were removed and thyroid hormone was added  
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Western Blot: 
Whole cell extracts used to determine the level of the protein of interest, cells 
were harvested in cold 25 mM Tris (pH 7.4), 1 mM EDTA, 1% SDS, 1% Triton 
X-100, 150 mM NaCl containing protease and phosphatase inhibitor cocktails 
(PIs; Roche Diagnostics), sonicated and then centrifuged 30 min at 15,000 
rpm. Protein concentration were determined by absorbance using 
spectrophotometer ND-1000 from Thermo Scientfic (Philadelphia, PA). Ten 
micrograms of protein were loaded into each lane in the gel. A broad-
spectrum molecular weight ladder (Precision Plus Protein, CA) was run on 
each gel. After separation, proteins were transferred onto Millipore Immobilon-
FL membranes and blocked in PBS with 0.1% Tween-20 (PBST) and 5% milk 
for 20 minutes at 4 °C. Membranes were incubated overnight at 4 °C with 
primary antibodies in PBST + 5% milk. Primary antibodies to the following 
antigens were used: MBP (SMI-99, dilution 1:1000), p-eIF2α (1:1000), total 
eIF2α (1:1000). Loading controls were obtained by using α-tubulin (1:1000 
dilution). Membranes were visualized using an Odyssey Infrared Imaging 
System (LiCOR).  
 
Mass Spectrometry:  
Oligodendrocytes primary rat cells were treated for 1 hour and 7 hours with 3 
µM RIT or the vehicle DMSO with sodium A Acetate (1-13 C 99%) for labeling 
at concentration of 1000µM,[156]. The samples were processed at Smilow 
Center of the University of Pennsylvania.  
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Statistical analysis: 
All data are expressed as mean with SEM. Data were analyzed with Prism 8 
(GraphPad Software). Differences between groups were assessed using one-
way ANOVA (Unpaired).  
3.4 Results: 
RIT is a member of the protease inhibitor class of antiretroviral drugs. It acts 
on the late stage of viral replication resulting in an immature virus that can’t 
infect intact cells [157]. RIT is among the oldest antiretroviral drugs, but 
remains in use today as a booster to enhance the pharmacokinetics of other 
antiretroviral drugs due to its inhibition of cytochrome P450 in the liver and 
intestine[14, 158-160]. Interestingly, individuals on RIT showed a decrease in 
HDL (High density lipoprotein), cholesterol level and an increase in total 
cholesterol level, LDL (Low density lipoprotein), and triglyceride levels [161]. 
We have previously shown a decrease in the number of differentiated 
oligodendrocytes and myelin proteins when oligodenodrocyte precursor cells 
(OPCs) were treated with RIT during a differentiation paradigm, but the 
mechanism behind this effect is still unknown[11]. We placed oligodendrocyte 
progenitor cells in differentiation medium with or without RIT and performed 
western blotting for SREBP1c protein after 72 hours. Our results show that 
the amount of the SREBP1c protein expression is elevated when OPCs were 
treated with 3µM RIT for 2 hours and 24 hours (Figure 15). 
We measured levels of three key enzymes in the lipid synthetic pathway, fatty 
acid synthase (FASN), acetyl co-A carboxylase (ACC) and 3-hydroxy-3-
methyl-glutaryl-coenzyme A reductase (HMGCR). We saw a significant 
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increase in the protein expression level of FASN at 24 and 72 hours in RIT 
treated cells compared with vehicle treated OPCs, but no significant 
difference was noticed for HMGCR or ACC (Figure 16). We then measured 
the accumulation and de novo synthesis of palmitate and cholestrol using 
mass spectrometer. The palmitate is an intermediate compound in the 
synthesis pathway of many sterols . Our results show around 50% increase in 
the newly synthesized cholesterol and palmitate in OPCs treated with 3µM 
RIT in concert with differentiation medium for 72 hours, and labeled with 13C 
acetat for the last 24 hours (Figure 17).  
 
3.5 Discussion: 
SREBPs are important regulators for cellular lipogenesis and lipid 
homeostasis but their role in oligodendrocyte myelination is not well-
understood. We have previously shown that treatment of oligodendrocyte 
progenitor cells with the protease inhibitor RIT resulted in an inhibition of 
differentiation but we did not identify a mechanism. It is known that RIT 
increases sterol synthesis by increasing SREBP1 expression in the liver and 
adipose tissue and sinc the myelin membrane is 70% lipid, we hypothesized 
that SREBP1 might also be increased in oligodendrocytes upon RIT 
treatment. The present study suggests that SREBP levels can be 
dysregulated when oligodendrocyte differentiation is decreased. Since 
generation of the myelin membrane with proper placement of lipids and 
proteins is necessary for process extension, it is possible that the alterations 
in balanced lipids in oligodendrocyte membranes caused by RIT resulted in a 
reduction in the total number of differentiated cells. The preservation of proper 
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cell membrane fluidity is important for diffusion of membrane components 
including different lipids and proteins and is necessary for the dynamics and 
function of membrane proteins. The alteration in lipid synthesis was identified 
on the level of the transcription factor SREBP1, in a key enzyme necessary 
for synthesis of the lipids and in the end product lipids themselves suggesting 
that an excess of SREBP1 caused by RIT treatment resulted in an alteration 
in the cells membrane normal dynamics and functions [162]. Our lab 
published previously that inhibiting SREBPs protein through S1P inhibitor 
resulted in a significant reduction in the maturation in the oligodendrocytes 
maturation [13]. Our current study suggests that a balanced amount of 
SREBP is required for normal maturation of oligodendrocytes. In conclusion, 
we show that SREBPs could play an important role in oligodendrocyte 
maturation and myelination. Inhibition or induction of SREBP may prevent 
process extension, and cellular maturation. All these effects may contribute to 
impaired myelin packing in the membrane.  
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3.6 Figures  
 
Figure14: Lipid enzymes in oligodendrocytes. reduction or elevation in the 
lipids enzyme in oligodendrocytes will result in disruption in the harmony in 
the process of cell membrane extensions.  
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Figure 15: SREBP1 expression is increased at 2 and 24 hours after ritonavir 
treatment. Western blot measuring SREBP1 protein level at three different 
time intervals, 2hours, 6hours and 24hours shows a significant increase in 
SREBP1 level in the group treated with Ritonavir at 2 and 24 hours when 
compared to the group treated with vehicle (DMSO). N=3, One Way ANOVA, 
* P<0.05, **P<0.001  
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Figure 16: Ritonavir treatment of OPCs significantly ncreased expression of 
FASN but not ACC or HMGCoAR. Western blot measuring lipid enzymes in 
differentiated oligodendrocyte precursor cells; A) a significant increase in the 
FASN protein level when treated with Ritonavir at both 24 and 72 hours 
compared to OPCs treated with vehicle (DMSO), B,C) there were no 
significant difference at protein level of both ACC or HMG Co-A when treated 
with Ritonavir compared to OPCs treated with vehicle. N=3, One Way 
ANOVA, * P<0.05, **P<0.001 
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Figure 17: Ritonavir increased levels of newly synthesized palmitate and 
cholesterol. OPCs treated with DMSO (vehicle) with or without 3µM of 
ritonavir for three days, 13C acetate was added to the differentiation media for 
the last 24 hours of treatment. Both newly-made palmitate and cholesterol are 
increased in cells labeled with acetate compared to DMSO-treated or 
untreated groups.N=3, * P<0.05,** P<0.01  
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CHAPTER 4: Discussion and Future Directions 
ART plays a major role in the attenuation of viral replication and boosts 
immune system recovery, but still we see that treatment results in adverse 
side effects, including cellular impairments which may contribute to the 
continued incidence and progression of HAND [25, 29, 32, 163-166]. We 
anticipate that some classes of ART drugs are involved in inhibiting the 
differentiation of oligodendrocytes using one or multiple pathways. The 
rationale for testing the effect of EVG on the maturation and differentiation of 
oligodendrocytes was for several reasons. First, EVG is currently part of the 
front line therapy for treating HIV adults according to the latest 
recommendation from both the World Health Organization (WHO) and USA 
guidelines [9, 14]. Second, last year we reported that EVG was toxic to 
neurons in primary neuroglial cultures as determined by measuring the 
Microtubular Associated Protein 2 (MAP2) [12]. This neurotoxic effect of EVG 
was associated with an elevation in the level of phosphorylated eIF2α and 
could be reversed by an inhibitor of phosphorylated eIF2α translation 
attenuation [12]. Human studies show persistent white matter damage in 
patients with HAND, despite effective reduction of viral load in plasma. 
Furthermore, the white matter loss is associated with the duration of both the 
infection and duration of the cART. Additionally, transcriptome analysis shows 
alteration in myelin genes following HIV infection which continued to be 
dysregulated in patients who display viral suppression via cART but were 
diagnosed with HAND [11, 70, 74]. All of these findings lead us to question if 
EVG affects the ability of oligodendrocyte precursor cells to differentiation into 
mature oligodendrocytes. Since the literature lacked information on this 
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subject we started our investigation on the effect of the EVG on  myelination 
and maturation of oligodendrocytes and its role in the development of HAND.  
EVG is commercially available in two different combinations. The first 
combination from Genvoya pharmaceutical company includes; EVG 150mg, 
COBI 150mg, Emtricitabine (ETC) 200mg, and Tenofovir Alafenamide (TAF) 
10mg.  The second choice is from Stribild pharmaceutical company EVG 
150mg, COBI 150mg, ETC 200mg, and Tenofovir Disoproxil Fumarate (TDF) 
300mg [9, 167]. The dose used in our in vitro studies was based on Cmax 
plasma concentrations in patients [44]. Our lowest in vitro dose was one tenth 
of that, the middle dose was equal to the Cmax plasma concentration and the 
highest dose was equal to three times the Cmax plasma concentration [129, 
168]. For the in vivo model, we used mass spectrometry to compare plasma 
levels from mice treated with EVG/COBI to plasma levels in treated patients 
and found mouse plasma levels comparable with those reported  in human 
plasma (Table 4) [135].  
 
 Time point Average Plasma Conc. in 
µg/ml 
C max 4 hours 1.96 
C min 4 days 0.370 
 
Table 4: EVG Plasma concentration in human; EVG pharmacokinetic 
parameters following administration of EVG/COBI , the plasma concentrations 
were obatained using mass spectrometry from human after administration of 
the drug orally (PO). N=10 [135].  
 
These studies investigating the effects of EVG in-vitro and in-vivo provide new 
and compelling evidence that EVG negatively impacts oligodendrocytes 
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maturation. EVG impairs OPC maturation both in-vitro and in-vivo. Using 
stage-specific markers, EVG but not RAL inhibited the maturation of OPCs 
and significantly reduced the expression of MBP. This effect is mediated at 
the transcriptional level since our qPCR result showed a dose dependent 
reduction in MBP mRNA in cells treated with EVG. Interestingly, the effects of 
EVG are reversible at 3.5µM but not at 10µM, despite minimal cell loss at 
either dose. Many reasons may contribute to this observation, such as failure 
to remove all the EVG during the washout step or the need for a longer 
recovery time.  
We were able to rescue OPC differentiation from the effects of EVG in vitro 
using an inhibitor of eIF2α phosphorylation translation attenuation, similar to 
our observations on the effects of EVG in neurons. Next, we looked at a 
protective cellular pathway called the integrated stress response ISR. This 
pathway can be activated due to a number of cellular stressors that result in 
the activation of one of four kinases resulting in phosphorylation of the eIF2α 
and global translation attenuation. In order to reverse the activation of the ISR 
we used a small molecule called TRANS-ISRIB to inhibit the global translation 
attenuation of eIF2α phosphorylatio with a dose shown to be protective in 
neurons [12, 169]. We found that pretreating the oligodendrocytes 1 hour prior 
to the treating the cells with different doses of EVG, and we found that it could 
protect the cells at 3.5µM but not at 10µM. More work is needed to 
understand the mechanisms by which 10µM EVG prevents OPC 
differentiation into mature oligodendrocytes.  
To examine the effect of EVG in vivo, we used the cuprizone (bis-
cyclohexanone-oxaldihydrazone) model, which is a neurotoxicant used as 
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model to study the demyelination and remyelination in the CNS. Cuprizone is 
a copper chelator that induces demyelination after 5 weeks of feeding (0.25% 
cuprizone mixed with normal powder food). By the end of the 5th week, gross 
demyelination will be observed especially in the corpus callosum (CC) with a 
concomitant increase in astrogliosis and microgliosis. A compensatory 
increase in oligodendrocyte progenitor cells will also be seen in the CC. 
Switching back to normal diet will result in remyelination of the CC, showing 
that cuprizone has a reversible effect in vivo [77, 140, 170]. In our experiment, 
we used COBI as a booster for EVG, and we tested the effect of the 
EVG/COBI by delivering the drug using IV cannula to the jugular vein after the 
5th week of cuprizone administration to mice. To observe the effect of the drug 
on mature oligodendrocytes (in the mice receiving normal diet) and on 
immature oligodendrocytes (in the mice receiving cuprizone) and to determine 
if EVG/COBI will interfere with the normal remyelination process during the 
recovery period after cuprizone-induced demyelination. At the 5th week, we 
inserted IV cannulas for the administration of the drug and switched the mice 
back into a normal diet without cuprizone. We found that EVG/COBI 
attenuated normal remyelination, resulting in similar numbers of 
oligodendendrocytes and myelin as the group that received cuprizone in their 
diet for 5 weeks. The group of mice receiving cuprizone and EVG/COBI also 
showed an increase in GFAP positive cells, IBA1 positive cells, and NG2 
positive cells as shown in Figures 11 and 12. These findings suggest an anti-
inflammatory agent might protect the oligodendrocytes from the effects of 
EVG in vivo. This study gives an insight into what might be happening to 
oligodendrocytes in rodent models, suggesting that white matter pathologies 
seen in HAND may be a result from the combined effects of cART and HIV. 
Also, since we did not see a change in myelination when EVG/COBI was 
administered to control animals who had not received cuprizone, EVG/COBI 
may have an effect on the developing oligodednrocytes but not on the mature 
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oligodendrocytes, implying that EVG affects the normal turn over of new 
oligodendrocytes and/or remyelination after an insult. This project has a great 
importance in adding knowladge and clinical value for treating HIV patients 
with the EVG. In our analysis of the in vivo effects of Elvitegravir, we observed 
changes in myelin staining and immunofluorescence of other proteins in the 
CNS using immunohistochemistry [140, 172, 173]; however, due to limitations 
in isolation of the corpus callosum for immunoblot analysis, we were unable to 
validate our changes using a biochemical approach. Immunohistochemistry is 
widely used in basic research and for aiding in clinical diagnosis of many 
neurodegenerative diseases, the data obtained from these experiments is 
only semi-quantitative  [174]. In an attempt to minimize subjectivity in our 
results, we have followed standard and published methods and techniques to 
support our interpretations [140, 172, 173]. Specifically, we used a masked 
observer to assign scores for myelin staining  intensity combined with a 
computerized, automated image analysis  to minimize human bias and error 
in the interpretation of the data.  
 
Elvitegravir is not the only ART compound that causes white matter 
pathologies, we have simultaneously been investigating the mechanism of 
RIT mediated effects on OPC maturation. We began our studies investiagting 
the effect of RIT on the maturation of oligodendrocytes because we had 
observed previously that RIT attenuated maturation of oligodendrocyte in vitro 
but the mechanism remained undetermined [11]. Further, guidelines from 
WHO urge that all infected children younger than 3 years old be treated with 
RIT in combination with lopinavir as first line of treatment, which is a critical 
period for myelination [14, 171]. The dose used in my studies was qual three 
times the physiological concentration in the human plasma level [11]. Lipid is 
a major component of myelin and any disruption in the normal balance of 
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lipids in oligodendrocytes will result in disruption of the normal development of  
oligodendrocytes from the precursor stage into the mature form. Previosuly 
our lab published inhibiting the SREBP from entering the nucleus by using 
S1P inhibitor caused a significant reduction in the number of differentiated 
oligodendrocytes [13]. So we tested the effect of RIT on SREBP protein 
expression in vitro. Unexpectedly, we found that SREBP protein expression 
was increased along with the lipid enzyme FASN, both of  which are 
responsible for the production of fatty acids. To confirm that the increase in 
the enzymes translated into an increase in the product, we examined the 
levels of palmitate and cholestoral using mass spectrometry and we found an 
increase of 50-60% in both the total mass of the newly synthesized palmitate 
and cholesterol in response to RIT. One explanation for this phenomenon 
could be that RIT changes the fluidity and stiffness of the oligodendrocyte 
membrane leading to a reduction in the differentiation of the oligodendrocytes. 
There may be other mechanisms at the play but this is one way in which RIT 
may contribute to the observations. More attention should be given to this 
drug especially given its recommended use for treating HIV children at critical 
age for myelination. In conclusion, even though ART improved the mortality 
and morbidity rate and overall the quality of life of HIV patients, more studies 
are needed to evaluate the effect of ART given to HIV-patients in CNS in 
general and the maturation process oligodendrocytes in particular. 
 
Future direction: 
I would like to proceed working on the effects of EVG on oligodendrocyte 
myelination, in the recommended treatment combinations: 1) EVG, COBI, 
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ETC, and TAF or 2) EVG, COBI, ETC, and TDF. The working novel model 
that we have developed using infusion of ART following cuprizone-induced 
demyelination will provide insight into the effects of compounds during the 
development of oligodendrocytes druing ART treatment, suggesting that this 
model could be used for evaluating the development of oligodendrocytes in 
pediatric models, during the normal turnover of the oligodendrocyte, or during 
injury. To reverse the effects of EVG on oligodendrocyte maturation and 
myelination, the literature suggests that the HIV viral protein, Tat, binds to the 
NMDA receptor, leading to a disruption of cytoplasmic Ca2+ homeostasis. 
Therefore, we could try blocking the effects of EVG by using an NMDA 
receptor inhibitor such as MK801[101]. Also, we demonstated previously that 
oligodendrocytes could be rescued from the effect of EVG at a 3.5 µM dose, 
but not at the 10 µM dose using eIF2α inhibitor TRANS-ISRIB in vitro. 
Therefore we could try attenuating the effect of EVG using TRANS-ISRIB in 
vivo [175]. Next, I would like to test the contribution of ART in HAND in the 
context of behavioral changes, brain anatomy assessed by radiographic 
images in the animal model. All of these tests will give us more understanding 
of the role of the ART in HAND.  
For the role of SREBP, it is known that the majority of ART drugs cause a 
disturbance in lipid homeostasis in the liver [66], but limited literature has 
examined the effect of these drugs on oligodendrocytes despite the major role 
of lipids in the function of oligodendroctyes. Studying the effect of ARV on 
SREBP in  oligodendrocytes will give us a great insight into the mechanism of 
development of HAND in HIV-positive patients.  
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Finally, I would like to use my experience in dentistry and to study the 
myelinated nerve axons inside the tooth pulp, since it is part of the body and 
linked to the CNS. Unlike other organs, the teeth are compactly innervated by 
primary sensory neurons found in the trigeminal ganglion, the two main nerve 
fibers in the teeth are A-fibers (δ- β) and C-fibers, the A fibers end in the inner 
one third of the dentin layer and the fibers located mainly in the pulp 
tissue[176, 177]. Unlike A fibers, C fibers are not myelinated and transmit the 
signals at much slower rate compared with  A fibers[178]. Schwann cells 
myelinate the nerve axon in the Peripheral Nervous System (PNS), it has 
similar action to the oligodendrocytes in the CNS in saltatory conduction, but 
they have a different development and assembly of myelin, plus they do not 
have a cytoplasmic projection and can myelinate only one neuron axon[179]. 
Currently, the most common side effect from HIV in the PNS is peripheral 
neuropathy plus other complication, and ART did not decrease these side 
effects[180]. Comparing number of surfaces with caries between HIV-positive 
patients and un-infected patients shows that HIV patients have significantly 
higher number of carious surface.[181]. The mechanism behind this remains 
poorly understood and I would like to examine the difference between myelin 
proteins inside the teeth and examine the impact of HIV and ART on nerve 
fibers in the oral cavity.  
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